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INTRODUCTION 
 
 
During my graduation thesis, focused on the oxidative chemistry of 17β-estradiol (17βE) in 
biomimetic conditions, I had the opportunity to understand what “to engage a topic of research” 
means; mine was addressed to define, on chemical bases, structural modifications of estrogens and 
other steroids derivates in pathologic conditions associated to oxidative stress. 
17βE represents with estrone and estriol a particular group of steroid hormones (estrogen 18C, i.e. 
eighteen carbon atoms) with estrogenic properties in mammals and men.1 In particular, 17βE is the 
major specific activity hormone and it plays a key role in the control of sexual behaviour and 
development as well as in a variety of processes related to reproduction.  
These functions were discovered in 1922 owing to the studies of American biochemists Edward 
Doisy and Edgar Allen on mouse ovaric extracts. The same Doisy isolated 10 mg of 17βE from 4 
ton of sow ovaric tissue in 1935. After the structural characterization of the estrogens, two Swiss 
scientists Karl Miescher e Georg Anner prepared estrone and 17βE via a chemical synthesis. This 
step had a great practical and social outcome because the synthesis of these hormones allowed the 
estrogen pharmaceutical use. The isolation from natural sources such as animal tissues would have 
required ovaries of two million sows to obtain 10 g of 17βE. 
In 1941 Hans Selye demonstrated the anaesthetic and sedative function of progesterone and its 
modulation of intracellular mediators.2 The presence of steroidal receptors on the cell membranes 
prompted a French researcher, Emile Baulieu, to look for steroids in nervous system. After some 
efforts steroidal hormones were found in animal brain.3 Baulieu introduced the term “neurosteroid” 
to designate steroids that are synthesized in the nervous system either de novo from cholesterol or 
by in situ metabolism of blood-borne precursors, and that accumulate in the nervous system to 
levels that are at least in part independent of steroidogenic gland secretion rates.4 In contrast to the 
circulating steroid hormones, which act at a distance from their gland of origin, on brain and 
neurons at relatively low concentrations (endocrine effect), neurosteroid hormones act in the 
nervous system in an auto/paracrine configuration.4 
The main activity of these neurosteroids in the central and peripheral nervous system appear to be a 
neuroprotective and neurotrophic action.5 Indeed they also may induce some kind of cancer and this 
have been attributed, at least in part, to the inherent susceptibility of the phenolic A-ring to 
enzymatic or chemical oxidation.6 So the investigation of structural modifications suffered by 17βE 
in oxidative settings is central for the understanding of the molecular mechanism underlying these 
properties. In addition, beyond the specific relevance to the steroid sector, the oxidation of estrogen 
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compounds represents an attractive research issue because of its potential as convenient entry to 
complex functionalized scaffolds of academic and industrial interest. 
In view of that, this work comes as an in-depth study on estrogen oxidative chemistry with a double 
target. The understanding of the molecular mechanisms of neuro- and cytoprotective activities as 
well as carcinogenic activities of 17βE on one side; the exploitation of oxidative transformations as 
access routes to new steroidal scaffolds of potential relevance to biomedical and pharmaceutical 
matters, on the other.  
The results are collected in two chapters: the first contains studies on oxidative chemistry of 17βE 
in biomimetic conditions; the second describes procedures for the preparation of estrogenic 
derivates that are halogenated, oxy-functionalized and/or desaturated at the steroidal backbone. 
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CHAPTER I 
 
Oxidative chemistry of 17βE related to biological activity 
 
 
17βE and estrogenic hormones originate from cholesterol by a series of enzyme catalyzed processes 
mainly located at the ovary, the kidney cortex, the placenta and for a few species, at the testicle.7 
The biosynthesis of 17βE, including enzymes involved in each step, is summarized schematically in 
figure 1. 
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The first step in this scheme of steroid biosynthesis corresponds to the formation of pregnenolone 
(PREG) from cholesterol. This reaction is catalyzed by an enzyme located at the inner 
mitochondrial membrane, the cytochrome P450scc, which removes 6 carbons from the side-chain of 
the cholesterol molecule (scc for side-chain cleavage). The newly formed PREG then leaves the 
mitochondria for the endoplasmic reticulum, where it is converted to testosterone, the androgenic 
hormone direct  precursor of 17βE, by two alternative metabolic pathway which differ in the 
sequence of this two step: a) oxidation of alcoholic function at the C3 position of PREG and 
isomerization of double bond in C5-C6 by the enzyme 3β-hydroxysteroid dehydrogenase, b) 
oxidation at the C17 with removal of the two carbons residue by cytochrome P450c17 enzime.5 
Fig. 1: biosynthetic pathways of 17β-estradiol 
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Finally an aromatase does oxidize testosterone to the phenolic steroid E, with a simultaneous 
demetylation at carbon 10.  
The action of estrogens on target cells (cells that synthesize nuclear proteins known as estrogen 
receptors) is a genomic one and carries on by regulating the transcription of hormone-sensitive 
genes. Once the steroids (i.e. estrogens) are formed, they easily diffuse, thanks to their lipophilicity, 
out of the cell membrane and into the blood where a plasma protein may transport them and release 
at the lipidic membrane of the target cells. Upon binding of estrogen to its protein receptor on the 
nuclear membrane, the receptor 
undergoes a conformational change 
leading to transformation into its active 
form. The receptors then dimerize and 
bind to the estrogen response element 
(ERE) of the targeted gene. The 
binding, therefore, induces a complex 
with RNA polymerase which actives the 
transcription of specific genes in mRNA 
molecules leading to the production of 
proteins by that cell to cause the 
physiological response.8 Through a 
genomic mechanism, estrogen 
hormones regulate menstrual cycle, 
induction of luteolyse and other processes associated to reproduction such as embryo’s nest in the 
uterus and prolactin biosynthesis.  
Other functions, that are typical of steroidal hormones, are the control of muscle tissue growth, the 
morphological determination of bones and modulation of various inflammatory responses.1 
Recent studies have documented steroid hormones (mainly estrogenic hormones) influence on 
processes in central nervous system activity. Although these functions still await elucidation, 
current views attribute neuroprotective and neurotrophic properties of E and correlated 
metabolites.9-11 Clinical studies demonstrate that estrogen replacement therapy in postmenopausal 
women may enhance cognitive function, decrease the risk of brain injury associated with ischemia 
and neurotrauma.12-15 Moreover E reduces neurodegeneration associated with Alzheimer’s and 
Parkinson’s diseases16-19 and influences memory and cognitive processes.20 Similar results have 
been obtained from studies on animal models in which estrogen administration significantly 
attenuates the degree of striatal dopamine depletion by neurotoxins (MPTP, 6-hydroxydopamine 
Fig. 2: the genomic mechanism of action estrogens 
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and methamphetamine).21-25 A number of studies establish that estrogen replacement therapy 
decreases cardiopathic risk and thrombosis, showing a protective effect of estrogens on the 
cardiovascular system, and that E decreases low density cholesterol in blood.26-28 
Following the observation of the various functions of 17βE and other steroid hormones in central 
nervous system the search for steroidogenic pathways in the brain was undertaken .4, 5, 29 In fact the 
synthesis of 17βE from pregnenolone has been evidenced in the astrocytes, star shaped glial cells 
that form cerebral connective tissue and that are present in gray and white matter of the brain. 4, 30 In 
these tissues are also active metabolic transformations of  17βE in hydroxylated derivates known as 
catechol estrogens (CEs) catalized by enzymes (i.e. cytochrome P450 and estradiol 2-
hydroxilase).31-33  
Currently, the term neurosteroid or neuroactive steroid is applied to those steroids that are 
synthesized in the nervous system or de novo from cholesterol or by in situ metabolism of blood-
borne precursors.4 These steroids act, such as other psycoactive substances (benzodiazepine, 
barbiturates, convulsivants) as if they were allosteric modulators of the γ-aminobutyric acid 
receptor type A (GABAA-R), NMDA, and sigma-1 receptor activities. 34, 35 There are steroids which 
either positively or negatively modulate the GABAA-R, for instance some are GABAA agonists (3α-
hydroxy-5α-pregan-20-one and androsterone), some are GABAA antagonists (pregnenolone e 
DHEAS).4 
 
Several studies have shown that estrogen receptors (ER) play a pivotal role in mediating 
neuroprotective actions of 17βE. They are distributed widely throughout the central nervous 
system, act as intracellular transcription factors and are part of the nuclear receptor super-family.36 
There are two ER subtypes, ERα and ERβ, and the deletion of ERα completely abolishes the 
protective actions of 17βE in all central nervous system; whereas the ability of 17βE to protect 
against brain injury is totally preserved in absence of ERβ.37, 38 These results clearly establish that 
the ERα subtype is a critical mechanistic link in mediating the neuroprotective effects of 17βE. 
Moreover, other potential means by which estrogen can function as a neuroprotectant are: its 
capacity to affect monoamine oxidase39 (enzyme that rules the turn-over of catecholamine 
transmitters) and its influence on membrane morphology and fluidity.40  
In vitro experiments show inhibition of lipidic peroxidation,41 production of prostaglandine and 
trombossani42 and of lipopolysaccharidic inflammatory mediators.43 
Despite lots of in vitro and in vivo experiments, very little is known about the neuroprotection of E 
in oxidative stress conditions at molecular level.44, 45  
This property is independent of estrogen stereochemistry and a mechanistic hypothesis proposes E 
as lipophilic scavenger of oxygenated species, generated in oxidative stress conditions and related 
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to neurodegenerative processes. 46, 47 This interpretation is based on evidence that the isomers 17α 
and 17β exert comparable protective effects,39 so it appears reasonable to rule out receptorial 
effects, and on biochemical data that show the sensitivity of E to oxidation, generating hydroxylated 
products (catechol estrogens). Therefore E performs the neuroprotection by inactivating ROS 
(H2O2, ˙OH, O2-.) and generating catechol estrogens. The ROS are produced in biological systems 
in physiological conditions, but in particular situations (i.e. presence of xenobiotics, cytotoxic 
drugs, ionizing ray) they are over-produced, as in oxidative stress conditions.   
In view of that, a detailed elucidation of the structural modifications suffered by E in oxidative 
settings is central for the understanding of the nongenomic effects of estrogens. Despite the many 
prospects offered by oxidative manipulation of estrogens, current knowledge in the field is 
surprisingly limited. Indeed when I begun the experimental activity here reported the only known 
oxidation products include, besides the catechol estrogens, a 10β-hydroxyestra-1,4-dien-3-one 
derivative arising by peracid-induced photooxygenation or oxidation by Fenton reagent,48 a series 
of benzylic oxidation species of estrone methyl ether,49 and two dimers obtained by chemical and 
enzymatic oxidation of E, namely, the symmetric 2,2’ and 4,4’ dimers.50 Other studies have 
appeared reporting formation of oligomer species by oxidation of E, but their characterization relied 
only on evaluation of chemical physical properties.51 More recently, a convenient synthetic access 
to O-linked dimers of E was reported52 in the frame of a study of the NADPH-dependent 
metabolism of E by human liver microsomes and cytochrome P450 enzymes. These latter studies 
and the vast body of literature on the oxidative coupling of phenols53 suggest that oxidative 
conversion of E and related estrogens in vivo can lead to an array of oligomeric products, yet their 
nature and biological properties have remained so far poorly elucidated. 
 
The study of oxidative chemistry of E also plays a pivotal role in the individuation of the molecular 
mechanism for carcinogenic proprieties associated to estrogen. In fact if estrogen replacement 
therapy has a variety of beneficial effects in vivo including protection against osteoporosis, 
coronary heart disease and stroke, Alzheimer’s disease,54 it is also true that disputed observations 
exist showing that, exposure to long-term high-dose estrogen replacement therapy increases the risk 
of developing breast or endometrial cancer in women.55 
Also for these activities the molecular mechanisms involved in the estrogens still remains both 
controversial and elusive. The role of estrogens in the induction of cancer has generally been related 
to stimulation of proliferation by receptor-mediated processes, that can lead an increased cell 
production. Although hormonal effects can mediate cell proliferation by receptor-mediated 
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processes, a genotoxic event seems to be needed to produce mutations, the permanent genetic 
changes at the origin of cancer.56  
A proposed mechanism might involve metabolism of estrogens to catechols, which are then 
oxidized to redox active/eletrophilic o-quinones that could initiate the carcinogenic process by 
binding to cellular macromolecules.55 For example, it is well established that the endogenous 
estrogens, estrone and 17βE, are metabolized via two major pathways: 16α-hydroxylation (not 
shown) and formation of CE, the 2-hydroxy and 4-hydroxy derivates (2OHE and 4OHE 
respectively) by P450 enzymes. Usually, these two CE are mainly inactivated by O-methylation 
catalyzed by catechol-O-methyltransferases. This conjugating pathway is protective because only 
the methylated and thus inactivated CE may be oxidized to semiquinones and quinones by 
peroxidases or P450 cytochromes.57 
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Catechol estrogen o-quinones (CEQs) are the reactive metabolites of catechol estrogens that are 
likely candidates for the ultimate estrogen carcinogenesis because of two main mechanisms. They 
can undergo redox cycling with the semiquinone radical, generating superoxide radicals (O2-.) 
mediated through cytrochrome P450/P450 reductase and/or other enzymatic/chemical redox 
couples.58 
Fig. 3: metabolic oxidative pathways of 17β-estradiol 
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The reaction of O2-. with hydrogen peroxide, formed by enzymatic or spontaneous dismutation of 
O2-., in the presence of trace amounts of iron or other transition metals gives hydroxyl radicals. The 
hydroxyl radicals are powerful oxidizing agents that may be responsible for damage to essential 
functional groups of macromolecules. For example oxidation of cysteine residues in proteins leads 
to disulfide bond formation which can dramatically alter structure and function. Hydroxy radicals 
can also catalyzed oxidation of lipids generating lipid hydroperoxides, and elevated levels in lipid 
hydroperoxides may damage structural and functional integrity of membranes because of the 
increase of permeability and the membrane enzymes inactivity. Furthermore the degradation of 
lipid hydroperoxides generates aldehydes and hydrocarbons that are very cytotoxic products. 
Finally, these radicals may cause oxidation of the phosphate-sugar backbone and/or the 
purine/pyrimidine residues of DNA. The resulting mutated bases could cause mispairing and 
mistake during the replication.  
The second potential mechanism of estrogen carcinogenesis is based on the electrophilicity of o-
quinones which can react with nucleophilic sites of DNA (nitrogenous bases) by Michael addition 
to form stable adducts that remain in DNA. Unless these alkylated bases are promptly repaired, 
miscoding may result during DNA replication, leading to mutations. 
Recent model studies with CEQs and deoxynucleosides or bases showed that different types of 
adducts are obtained:56 stable adducts that contain the deoxyribose moiety and that remain bound to 
DNA, depurinating adducts in which the glycosidic bond of dG or dA is destabilized, leading to 
loss from DNA and formation of apurinic sites. 
Fig. 4: catechol estrogens redox cycling 
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CEQs derived from 4OHE and 2OHE (CE-3,4-Q and CE-2,3-Q respectively) react differently with 
nucleosides and DNA because of their distinctive chemical properties. CE-2,3-Q binds to the 
exocyclic amino groups of dA and dG to form adducts that retain the deoxyribose moiety whereas 
CE-3,4-Q bind exclusively to the N-7 of Gua and to the N-3 of Ade, resulting in destabilization of 
the glycosidic bond and subsequent depurination.56  
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The species shown above result to arise via a Michael addition of nucleophilic groups in dG e dA to 
CEQs. In the reaction of CE-3,4-Q with dA or dG, attack of the nitrogen nucleophile at C1 is the 
result of 1,4-addition with the respect to the C3 carbonyl. This is in contrast to sulfur nucleophiles, 
which attack at the C2 position, a 1,6-addition with respect to the C4 carbonyl. Molecular orbital 
calculations have shown that, in neutral species, C1 bears more positive charge than C2 and the 
orbital LUMO has an higher coefficient at C2 than C1. Thus, soft nucleophiles, such as thiols, will 
attack at C2, while harder nucleophiles, such as nitrogen and oxygen, will attack C1. The products 
of the reaction of CE-2,3-Q with dG or dA are the result of a 1,6-Michael addition to the quinone 
after initial tautomerization of quinone to the more electrophilic quinone methide. Several studies 
indicate that CE-2,3-Q is more stable than quinone methide isomer. However the products of 1,6-
addition demonstrate that only the quinone methide isomer, presents in small quantities, reacts with 
these nucleotides.57 
These results are sustained by in vivo studies reporting, for instance, that the depurinating adducts, 
identical to those formed in vitro, have been identified in rat mammary gland after injection of CE-
3,4-Q.57 
Several lines of evidence suggest that the 4-hydroxyestrogens are critical intermediates in the 
pathways leading to estrogen-induced cancer. For example 4OHE induces renal tumors in hamsters, 
whereas 2OHE does not.59 Furthermore, an estrogen 4-hydroxylase activity has been identified not 
only in hamster kidney but also in other human and animal organs prone to estrogen-induced 
cancer, such as uterus, pituitary.57   
Fig. 5: CEQs adducts with dA and dG 
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The biological consequences of bulky DNA adducts and/or apurinic sites are difficult to assess. It is 
possible that the loss of these adducts generates apurinic sites in DNA, which have high potential to 
produce mutations in critical genes (oncogenes and tumor suppressor genes). This series of events 
can initiate cancer in a variety of human tissues.56 A similar relationship, for instance, exists 
between depurinating polycyclic aromatic hydrocarbons-DNA adducts and oncogenic mutations 
generated in cells culture.57 
The CE are inactivated by conjugation reactions such as glucuronidation and sulfation or by O-
methylation. If these conjugating pathways are insufficient and/or ineffective, the competitive 
oxidation pathway of CE turns out their semiquinones and quinones; usually these reactive 
quinones are inactivated by reduction to CE catalyzed by quinone reductase enzyme or by 
conjugation with GSH catalyzed by glutathione-S-transferase enzyme. If these inactivating 
pathways are nonetheless insufficient and/or ineffective, the CEQs may show their cytotoxic 
proprieties.56 
The conjugation CEQ-GSH results to be a detoxification way in biological systems because GSH 
reacts very rapidly with o-quinones and successfully competes with other nucleophilic residues in 
vivo and in vitro, it decreases the number of electrophilic sites in the quinone and by increasing the 
hydrophilicility, facilitates excretion.60 
The reaction of CEQs with a variety of sulphur nucleophiles (RSH where R = Cys, NAcCys, GS) is 
very intriguing in estrogen carcinogenesis.60 GSH adds at the 1- and 4- position in the case of o-
quinones from 2OHE, giving two mono-GSH adducts and one GSH adduct, and only at the 2 
position for the 4OHE o-quinone.55 (fig.X)  
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The CEQ-GSH conjugates and DNA adducts are identified in vivo and vitro cultures and are 
potentially useful as biomarkers to indicate both DNA damage and potential susceptibility to 
estrogen-related cancer.60 
It has been shown that in vitro the o-quinones of both 2OHE and 4OHE isomerize 
nonenzymatically to highly electrophilic p-quinone methides. CE-2,3-Q forms two quinone 
methides: a quinone methide stabilized by two alchyl substituents on the metylene group in the C 
ring and a quinone methide with only one alchyl substituent in the B ring. In contrast, CE-3,4-Q 
Fig. 6: CE adducts with GSH 
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only isomerized to the potentially more stable C ring p-quinone methide as the B ring o-quinone 
methide was not detected.55 
The different structure of CE quinone methide with o-quinones results in a much more reactive 
electrophile and in a reduced capacity for redox chemistry. Consequently, reactions of quinine 
methides in biological systems are characterized by non-enzymatic Michael addictions at the 
exocyclic methylene carbon, generating benzyling adducts of peptides, proteins and nucleic acids.55  
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In vitro experiments suggest that in cells with low levels of GSH the formation of these potent 
electrophiles represents the major reaction pathway for estrogen o-quinones.55  
These results, therefore, are index of the complexity of the CEQs conversion pathway and little 
attention has been paid to the nature of the products formed by conversion of the CEs beyond the o-
quinone stage. Yet, several interesting conversion pathways may be predicted based, for example, 
on recent studies of 2-hydroxy-8,9-dehydroestrone oxidation, leading to 2- and 4-
hydroxyequilenin.54, 61  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 7: isomerisation CE o-quinone to quinone methide 
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Oxidation of 17βE by the peroxidase/H2O2 system62 
 
In preliminary experiments, the ability of various chemical and enzymatic oxidants to induce 
conversion of 17βE to products was briefly investigated under different reaction conditions. With 
the chemical oxidants tested, i.e., persulfate, ferricyanide, and ceric ammonium nitrate, little or no 
substrate conversion was observed (HPLC and TLC evidence) in aqueous buffers or biphasic media 
in a broad range of pH values. With ferricyanide, slow substrate consumption was obtained only in 
0.1 M NaOH, as previously reported.50  
By contrast, a substantial substrate consumption was observed with the peroxidase/H2O2 system, 
with formation of a number of products whose chromatographic and spectral properties were 
suggestive of oligomer species. Moreover the occurrence of peroxidase in mammalian tissues 
responsive to estrogen activity, such as uterus,63 induced us to embark on the isolation and detailed 
characterization of the products formed by peroxidase/H2O2 oxidation of 17βE. 
In a typical preparative scale reaction, 17βE at 0.3 mM concentration was allowed to react with 
peroxidase (1U/mL) and hydrogen peroxide (2 mol equiv). After 60 min, with >98% substrate 
consumption, the mixture was extracted with ethyl acetate following careful acidification to pH 5.0. 
PLC fractionation afforded seven main chromatographic bands at Rf = 0.68, 0.55, 0.45, 0.43, 0.33, 
0.22, and 0.10 (eluant A) designated A-G, in that order. Of these, only fraction D consisted of a 
single species pure enough for spectroscopic analysis, whereas remaining fractions required further 
fractionation. The most polar band G was made of chromatographically ill-defined products, and 
their identity was not investigated.  
Spectral data (1H and 13C NMR) of the product from band D were in agreement with a C2-
symmetric dimer (molecular ion peak at m/z 542). Homo- and heteronuclear correlation 
experiments allowed straightforward formulation of the product as 1. 
Chromatographic band A consisted of an intimate mixture of two closely related species which 
could be separated by preparative HPLC. The products showed nearly identical 1H NMR spectra 
OH
OH
OH
OH
1
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featuring in the aromatic region two doublets (J = 8.8 Hz) at around δ 7.3 and 6.9, suggesting the 
C2-symmetric 4,4’ dimer 2.  
OH
OH
OH
OH
2
 
On this basis, the two products were regarded as atropoisomers arising by a restricted rotation 
around the sterically crowded biphenyl 4,4’linkage. No appreciable interconversion of the rotational 
isomers was observed by heating to 110 °C at which temperature the products began to decompose 
significantly. This implies that the activation energy barrier is greater than 22.5 kcal mol-1.  
The constituents of chromatographic band C as purified by HPTLC displayed very similar 1H NMR 
spectra showing in the aromatic region two singlets at about δ 7.0 and 6.8 and two doublets (J = 8.4 
Hz) at about δ 7.3 and 6.9, suggesting two atropoisomers of a 2,4’-linked dimer (3). 
 
This view was confirmed by dynamic 1H NMR experiments (see figure 8). Line shape analysis at a 
temperature around coalescence allowed calculation of the mean lifetime of the atropoisomers, and 
a free energy of activation of 21.5 ± 0.5 kcal mol-1 was determined by application of the Eyring 
equation: 
k = RTe
hN
RT  ∆−
‡G
                          
OH
OH
OH
OH
3
k = rate constant  
R = universal gas constant 
N = Avogadro’s number 
h = Plank constant 
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The two components of chromatographic band B were separated by preparative HPLC. The mass 
and NMR data led to straightforward formulation of the compounds as the O-linked dimers 4 and 
5.52 
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Extensive 2D proton-proton and proton-carbon correlation experiments allowed complete 
assignment of the aromatic resonances. All products from chromatographic bands E and F exhibited 
molecular ion peaks at m/z 812 in the EI-MS spectrum indicating trimeric structures. Products from 
band E as obtained in pure form by HPLC separation showed very close proton spectra and were 
regarded as atropoisomers. Both displayed in the aromatic region an ABX spin system and three 
singlets around δ 6.7, 6.9, and 7.0, consistent with a trimer in which a central estradiol unit is linked 
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Fig. 8: 1H NMR spectra of atropoisomeric dimers 4a and 4b mix 1: 1 at several temperatures 
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to the 2-position of an outer moiety and to the oxygen of the other unit. On the basis of the HMBC 
correlation data, it was possible to assign the signals at δ 7.04 and 6.75, for the faster HPLC eluted 
compound, to the H-1 and H-4 protons of the same estradiol unit. The shielding effect caused by the 
oxygen bridge, observed also in dimers 4 and 5, and the presence of a weak but well discernible 
cross-peak between the proton resonance at δ 7.04 and a substituted C-4 carbon resonance at δ 
124.3 allowed straightforward assignment of the former signal to the H-1 proton of the central unit 
leading eventually to assign the trimers structure 6.  
 
OH
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In these, the atropoisomerism is apparently the result of the restricted rotation around the 2,4’ 
linkage. NMR line shape analysis around the coalescence temperature allowed calculation of a free 
energy of activation of 20.9 ±0.4 kcal mol-1. 
Of the four main HPLC-separable products in band F, those eluting at 24 and 80 min (eluant II) 
interchanged on heating, suggesting again an atropoisomer relationship, whereas those eluting at 34 
and 37 min (eluant II) were not affected by heating to 100 °C. The aromatic region of the 1H NMR 
spectrum of the products eluted at 24 and 80 min displayed five singlets, a feature which was 
compatible with the trimeric structure 7. 
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Complete assignment of the proton and carbon signals in the aromatic region was achieved on the 
basis of the data of the correlation experiments. In particular, in the case of the slower eluting 
isomer (7b), the singlets at δ 7.21 and δ 6.76 were assigned to H-1 and H-4 protons of the same 
unit, respectively, on the basis of the 3J and 2J long-range contacts exhibited with C-3 and C-2 at δ 
151.1 and 123.0, respectively. A 3J contact between the latter carbon and the H-1’ proton at δ 7.32 
of another unit provided support to the 2,2’ linkage between two of the trimer units. The free energy 
activation for the interconversion was calculated as 21.3 ± 0.5 kcal mol-1. The 1H and 13C spectra of 
the other two constituents of band F were likewise very similar. The aromatic regions of the proton 
spectra diplayed three singlets and two doublets (J = 8.4 Hz), a pattern of resonance that was 
compatible with either of the two trimeric structures in which the estradiol units were linked 
through the 2,4’:2’,4’’ or the 2,2’:4’,4’’ positions. The lack of appreciable interconversion on 
heating, observed also for the atropoisomers of the 4,4’ dimer 2, strongly argued in favor of 
structure 8.  
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This assignment was confirmed by analysis of the proton-carbon correlation spectra showing 
contacts matching those of the 2,2’ subunit of trimer 7. Interestingly, when the oxidation of 17βE 
was carried out with the substrate at 0.3 µM concentration, that is, at a concentration close to 
physiological values, substrate consumption was >95% at 1 h and the main reaction products were 
the dimers 1 and 3, whereas the O-linked dimers 4 and 5 were formed only in very small amounts 
and dimer 2 and trimers 6-8 were below detection limits. For comparative purposes, the oxidation 
of 17βE with manganese dioxide in chloroform was briefly investigated. Under these conditions, a 
smooth oxidation of 17βE (>99% consumption after 20 h) was observed with formation of dimers 2 
and 3 as main species (about 30% overall formation yields) but with no detectable 1, 4, and 5. The 
different product patterns obtained at lower substrate concentration, or using manganese dioxide in 
chloroform, suggest that the generation and mode of coupling of phenoxyl radicals is under the 
influence of several factors. For example, tenuous steric factors may become significant under high 
dilution conditions, thus accounting for the lack of formation of the relatively hindered dimer 2, 
whereas solvent effects may explain the prevalence of C-coupling products, i.e. dimers 2 and 3 in 
chloroform, also furnishing a suggestion for preparative purposes requiring regiochemically more 
restricted products patterns. The sterically hindered biphenyl linkage in 2, 3, and 6-8 represents a 
stereogenic element which adds to those already present in 17βE. For all isolated products featuring 
such structural system, configuration at the biphenyl linkage (and thus absolute stereochemistry) 
was established by the exciton chirality method on the basis of the Cotton effect associated with the 
phenolic transition 1La, whose vector nearly overlaps that joining the C10-C3-O centers.64 This 
transition is observed at around 220 nm in 17βE in EtOH, but the formation of biphenyl linkages 
and the presence of other substituents, such as the O-linked unit in 6a,b, cause shift to longer 
wavelengths. The relative directions of the 1La transition dipoles and of the biphenyl bonds allowed 
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assignment of positive screwness configuration (P) to those isomers exhibiting positive Cotton 
effect independently from the regiochemistry of the biphenyl linkage. Indeed, geometry 
optimization of the oligomer structures (MM+) showed that the dihedral angle between the planes 
of the aromatic rings of the biphenyl system has an absolute value ranging from 43° 22’ to 45° 15’ 
for 2,4’ linkages and from 90° 02’ to 94° 92’ for 4,4’ linkages. On the basis of the angles between 
1La transition vectors and the dihedral intersection line, trigonometric calculations gave the range 
+37 to +77° for the angle between the dipole transition moments in the case of a positive dihedral 
angle. These values are significantly smaller than 110°, which is the theoretical zero point at which 
for polyphenyl systems featuring right-handed screwness64c the sign of the exciton split of CD 
Cotton effect changes from positive to negative, allowing straightforward molecular configuration 
assignment. The choice of 1La transition arises also from the clearly defined monosignated Cotton 
effect at around 230 nm in all isolated products, whereas the Cotton effect at ca. 280 nm (transition 
1Lb) was less defined for nearly all products, with the exception of those featuring 4,4’- biphenyl 
linkages. On this basis, the negative Cotton effect of the first HPLC eluted atropoisomer of 3 and 6 
(i.e. 3a and 6a) indicates a negative helical orientation of phenol transition moments that means an 
M molecular chirality, while the first eluted isomer of 2 has the P configuration (Figure 9 A-C). 
 
Fig. 9: CD spectra of compounds 2a (A), 3a (B), and 6a (C). 
 
In the case of 7 (i.e. 2,2’:4’,2’’-triestradiol) and 8 (i.e. 2,2’:4’,4’’-triestradiol) the first eluted 
isomers share the M configuration at the 4’,2’’ biphenyl linkage and at the 4’,4’’ linkage, 
respectively (Figure 10 A,B).  
 
 
 
 
 
 
Fig. 10: CD spectra of compounds 7a (A) and 8a (B). 
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Mechanistically, formation of oligomer products 1-8 by peroxidase/H2O2 promoted oxidation of 
17βE can be interpreted as involving generation and coupling of phenoxyl radicals from 17βE. 
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In the presence of H2O2, ferric peroxidase (ground state) generates the ferryl pi cation (compound I) 
via two electron oxidation. Compound I can then be reduced to compound II, the ferryl form of the 
enzyme, which has higher oxidative 
equivalents than the resting ferric form.63b 
Both compounds I and II can oxidize the 
phenolic moiety of 17βE to give the 
phenoxyl radical. From inspection of the 
SOMO and Mulliken spin densities of the 
phenoxyl radical of 17βE reported in a 
previous study,65 no appreciable difference 
was anticipated in the reactivity of 17βE 
through the 2 and 4 positions, in accord 
with experimental evidence. Coupling through the oxygen center is clearly a reflection of the high 
spin density at this site, in conformity with the known patterns of oxidative coupling of phenols.  
Concluding Remarks. Highlights of this study include (a) the first isolation and complete 
characterization of trimeric steroids linked through C-C and C-O-C bonds, (b) the first example, to 
the best of our knowledge, of atropoisomerism in steroidal systems, generated by steric hindrance to 
FeIV
FeIV
FeII
O
O
substrate
substrate
peroxidase compound I 
 peroxidase native form
H2O2
peroxidase compound II
H2O
oxidated substrate
oxidated substrate
Fig. 11: generation and coupling of phenoxyl radicals from estradiol 
Fig. 12: schematic peroxidase action 
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free rotation at 2,4’- and 4,4’-biphenyl linkages, and (c) the exploitation of peroxidase/H2O2 as an 
efficient and clean oxidizing system in estrogen chemistry. 
From the biomedical point of view, the present results offer an improved background to elucidate 
the chemical nature and fate of the products derived from the antioxidant and radical scavenging 
reactions or from oxidative changes of the estrogens at sites of inflammation and active metabolic 
transformation. In the light of the suggested role of 17βE as OH radical scavenger, generation of 
these oligomers may represent an alternative outcome of the radical scavenging action in addition to 
quinol formation.48 Oligomers 5 and 6 resemble the photodegradation products of ethinyl 
estradiol,66 and their formationby autoxidation and photodegradation of 17βE containing drugs can 
be predicted. C2-symmetric dimers bear considerable similarity to stereochemically related 
products67 currently under scrutiny because of their antiestrogenic activity and may represent 
attractiveprototypes/leads for the rational design of new bioactive steroids. 
Finally, atropoisomeric estradiol oligomers are analogous to para-polyaryls, which exhibit 
attractive structural features, such as helicity, and other connected unusual chemical-physical 
properties underlying a number of applications in material science.68 
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Scheme 1. Proposed mechanism tyrosinase’s action 
Oxidation of 17βE by the tyrosinase/O2 system69 
 
An oxidizing system that could model oxidative transformations of 17βE in vivo, thus enabling 
chemical studies of CEQs generation and fate, is tyrosinase.70-72 Tyrosinase is the key enzyme of 
melanogenesis in epidermal melanocytes72 and possesses both monophenol monooxygenase activity 
(EC 1.14.18.1, tyrosine, 3,4-dihydroxyphenylalanine:oxygen oxidoreductase) and o-
diphenoloxidase activity (EC 1.10.3.1, o-diphenol:oxygen oxidoreductase). Tyrosinase can act on 
monophenols (M) because of the mixture of met- (Em) and oxy-tyrosinase (Eox) which exists in the 
native form of the enzyme. The latter form is active on monophenols, while the former is not. 
However, the kinetics are complicated because monophenols can bind to both enzyme forms. This 
situation becomes even more complex since the products of the enzymatic reaction, the o-quinones, 
are unstable and continue evolving to generate o-diphenols (D) in the medium. A proposed kinetic 
mechanism to explain the enzyme's action is based on structural aspects developed by Solomon 
(Scheme z).73 Briefly, Eox would start the turnover by acting on M, which is hydroxylated to 
generate EmD. At this point the enzyme may oxidise D to Q, generating Ed, or release D producing 
Em, which would bind with M to produce the inactive form EmM.  
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Tyrosinase-like proteins have recently been identified in estrogen-responsive tissues as well as in 
the nervous system.74-76 Such enzymes from nuclear extracts were found to possess both cresolase 
and catecholase activity, as well as estrogen binding properties, and may thus play a role in the 
conversion of 17βE into its hydroxylated metabolites.  
Mushroom tyrosinase was selected as a convenient oxidizing system for producing CEQs from 
17βE and for monitoring their fate under physiologically relevant conditions. At variance with the 
mammalian enzyme from melanoma cells,77-79 which is apparently unable to induce estradiol 
hydroxylation, mushroom tyrosinase displays efficient cresolase activity toward this estrogen and is 
highly effective in causing catechol estrogen oxidation to CEQs.  
The reaction of 17βE with the tyrosinase/O2 system was examined with substrate concentration in 
the range 1nM-30µM in phosphate buffer at pH 7.4. For product determination, a work up 
procedure was developed, involving mild reductive treatment of the reaction mixture with sodium 
borohydride to halt the oxidation and convert quinonoid species to their reduced forms, followed by 
acidification to pH 5.0 and extraction with ethyl acetate. Substrate consumption and product 
formation were tracked by HPLC analysis of the ethyl acetate-extractable fraction.  
Typical elution profiles of mixtures obtained by oxidation of 17βE at 1 nM and 30µM 
concentration are reported in Figure 13a and 13b, respectively. A more complex reaction pathway is 
observed at higher substrate concentration. A preliminary ESI(-)-MS analysis of the HPLC eluates 
following ethyl acetate extraction indicated the presence of the catechol estrogens 2OHE and 4OHE 
along with a series of species with mass spectra suggestive of transformation products of 2OHE and 
4OHE. 
To test this hypothesis, in another series of experiments the tyrosinase-catalyzed oxidation of 2OHE 
and 4OHE was investigated under similar conditions.  
Tyrosinase promoted oxidation of 2OHE and 4OHE. The HPLC elution profiles of the oxidation 
mixtures obtained by oxidation of 2OHE and 4OHE at 30 µM concentration are shown in Figure 1c 
and d. The data suggest that peaks I and III-VII in Figure 13b arise from 2OHE whereas peak II 
derives from 4OHE. Accordingly, the oxidation of these catechol estrogens was repeated on a 
preparative scale and the products eluted under the main peaks were isolated by preparative HPLC 
and were characterized by extensive 2D NMR and mass spectrometric analysis.  
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Fig. 13: Elutographic profiles of the tyrosinase mixture reaction of 17βE at 1 nM (trace a), 30 µM 
(trace b), 2OHE (2) at 30 µM (trace c) and 4OHE (3) at 30 µM (trace d) after 3 h reaction time. 
 
 
 
 
c 
d 
a 
b 
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Preparative scale oxidation of 2OHE was carried out with 60 µM substrate and 5U/mL tyrosinase in 
vigorously stirred phosphate buffer at pH 7.4.  
The 1H and 13C NMR spectra, as well as 1H, 13C HMBC and HMQC experiments, suggested that 
the product eluted under peak I was 6-oxo-2-hydroxyestradiol (9). This conclusion was supported 
by a carbonyl carbon signal at δ 200.3, the lack of the benzylic methylene protons resonating at δ 
2.83, and the pseudomolecular ion peak at m/z 301 ([M-H], ESI(-)). Product 9 was previously 
obtained by MnO2 promoted oxidation of 2OHE in an organic medium,80 but has never been 
described among the products formed by oxidation of 17βE or 2OHE under physiologically 
relevant conditions. 
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The mass spectrum of the product eluted under peak III indicated a molecular mass 4 units lower 
than that of 2OHE. The aromatic region of the proton spectrum, featuring two singlets and two 
doublets, was suggestive of a dihydroxynaphthalene moiety. This conclusion was corroborated by 
1H, 13C HMBC experiments and comparison of the UV absorbance pattern with that of 2-
hydroxyequilenin,81 allowing eventually formulation of the product as 6,7,8,9-dehydro-2-
hydroxyestradiol (10). Compound 10 bears considerable resemblance to 2-hydroxyequilenin, which 
is produced by oxidative metabolism of 8,9-dehydroestrone via 2-hydroxy-8,9-dehydroestrone; 61 
however, to the best of our knowledge, it has never been obtained by oxidation of 17βE or 2OHE.  
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Peak IV proved to be due to an intimate mixture of two related products sharing the molecular mass 
of a dehydro derivative of 2OHE. Fractionation on silver nitrate-impregnated TLC plates allowed 
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eventually to isolate the products in pure form. These were subjected to extensive 2D homo- and 
heterocorrelation experiments and formulated as 6,7-dehydro-2-hydroxyestradiol (11) and 9,11-
dehydro-2-hydroxyestradiol (12). In the case of 12, significant NOE contacts could be observed 
between the H-1 and H-11 protons.  
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Products 11 and 12 were fairly stable in both acidic and alkaline media, without appreciable 
interconversion or degradation. 
Mass spectra of products from peaks V and VI suggested dimeric structures, one of which (peak VI) 
was 4 mass units lower than expected for a dimer. Extensive spectral analysis, including 2D NMR, 
eventually allowed characterization of the products as the dimers 13 and 14, respectively, in which 
the monomer units were linked through ether bridges.  
For product 13, substitution at the 1-position of one catechol ring was deduced from distinct long 
range couplings between the benzylic CH2 carbons on the 6- and 6’-positions and two aromatic 
protons at δ 6.28 and 6.08, indicating that the adjacent 4- and 4’-positions were unsubstituted. The 
involvement of the 3-OH group of the other catechol ring in the ether bridge was inferred from 
chemical shift analysis and, in particular, from the upfield shift of one of the H-4 protons of ca. 0.5 
ppm with respect to 2OHE (δ 6.58), suggesting an aryl ring on the adjacent OH group. Brief 
inspection of the geometry optimized structure of 13 (MM+) consistently indicated a spatial 
proximity of the H-4 proton to the aryl ring in a number of rotamers, whereby a shielding of at least 
0.5 ppm can be expected.82 Furthermore, the less pronounced upfield shift of the other H-4 proton 
(δ 6.28) was in accord with the shielding effect of a para phenoxy group.  
A survey of the literature indicated that a product related to 13, i.e. a 2-hydroxyestrone dimer 
featuring an o-quinone moiety, has been described.83 However, the close similarity of the aromatic 
proton spin systems and the facility of catechols to lose H2 in the EI source to give [M-2]+ peaks84 
raises the possibility that the product described by the previous authors was in fact the analog of 13 
in the estrone series. 
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Oxidation of 4OHE under the reaction conditions adopted for 2OHE proceeded at a slightly lower 
rate with respect to 2OHE (2.8x10-10 Ms-1 and 2.3x10-9 Ms-1, respectively), supporting previous 
observations on the higher oxidizability of 2-hydroxyestrogens compared to 4-hydroxyestrogens,85 
to give a single major product (peak II figure 13). This products was isolated and characterized as 
9,11-dehydro-4-hydroxyestradiol (15) on the basis of extensive NMR analysis and mass spectral 
data. 
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At variance with previous observations on the oxidation of 2-hydroxyestrone in an organic solvent, 
83
 we were unable to identify C-C coupling products of 2OHE and 4OHE in the oxidation mixtures. 
With the above products available, separate analyses were run to determine changes in product 
distribution with estrogen concentrations. The results showed that with 17βE at 1-10 nM 
concentration, main reaction products included 6-oxo-2-hydroxyestradiol (9), 6,7-dehydro-2-
hydroxyestradiol (11), 9,11-dehydro-2-hydroxyestradiol (12) and 9,11-dehydro-4-hydroxyestradiol 
(15), as apparent from Figure 1a, while 6,7,8,9-dehydro-2-hydroxyestradiol (10) and the dimeric 
products 13 and 14 were formed only at higher concentrations of 17βE, e.g. 1-30 µM. 
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Mechanistic remarks. Products 9-15 conceivably arise by conversion of catechol estrogens to the 
corresponding CEQs which may subsequently partition among different competing pathways, as 
schematically outlined in Scheme 2.  
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Scheme 2. Schematic outline of the proposed mechanism of formation of products 9-15 
 
Most of these pathways are proposed to involve transient quinone methide intermediates. These 
may undergo addition of water, as in the oxidative route to 9, or may isomerize to give the 
unsaturated derivatives 10-12 and 15 after oxidation/aromatization steps. Isomerization to p-
quinonemethides86 is an established conversion route of o-quinones which usually does not require 
enzymatic assistance.87, 88 However, the possibility that this reaction was promoted by laccase, 
which is present as a contaminant in the commercial preparations of mushroom tyrosinase,89 was 
considered. To this aim, the oxidation reactions were also carried out with carefully purified 
enzyme preparations according to reported procedures,89 and were found to give product patterns 
that were superimposable to those obtained with the crude commercial enzyme. Moreover, addition 
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of a specific tyrosinase inhibitor (tropolone)90 resulted in nearly complete suppression of substrate 
consumption and product formation.  
Whereas the CE-2,3-Q may give rise to two isomeric quinone methide intermediates, which appear 
to contribute equally to product formation when generated in the nM range, the 3,4-quinone can 
give rise to only one quinone methide, and it is possible that this difference accounts for the simpler 
oxidation mixture of 4OHE. In Scheme 1, dimeric derivatives 13 and 14 are proposed to arise from 
different coupling reactions. This conclusion was supported by separate experiments showing that 
13 is by no means converted to 14 when exposed to tyrosinase at pH 7.4, under the usual reaction 
conditions. However, redox cycling with intermediate oxidation products can not be ruled out. 
Indeed, dimer formation from catechol compounds may occur either by a one-electron transfer via a 
charge transfer complex83, 91 or by addition of 2OHE to the o-quinone via  the 3-OH group.  
Structures 13 and 14 would reveal a similar pattern of reactivity of the o-quinones of 2OHE and 10, 
favoring coupling at the hindered 1-position. In the case of 2OHE, this behavior was largely 
anticipated on the basis of the mode of dimerization of 2-hydroxyestrone.83 Yet, it was less obvious 
for 10, which would behave on oxidation like a highly reactive 2,3-naphthoquinone.92, 93  
 
Effect of nucleophiles on catechol estrogen oxidation. In further experiments, the effects of some 
nucleophilic compounds on the oxidation of the catechol estrogens at 10 µM concentration were 
investigated to assess the possible influence of potential biological targets in tumor induction and 
other estrogen-induced toxic responses. Selected nucleophiles included adenine,94 thymine,95 
cytosine,95 2-deoxyguanosine,80 imidazole83 and glutathione96, 97 for which the ability to trap CEQs 
was established. The effect of these compounds on the formation of 9-11  from 2OHE  and of 15 
from 4OHE was determined by comparing the HPLC traces of the organic extracts with those of 
control experiments carried out in the absence of additives.  
The data in graphics 1-4 of figure 14 indicated that with both catechol estrogens, glutathione was by 
the far the most effective inhibitor of product formation, due likely to the ability of thiols to cause 
quinone reduction and/or trapping.96  
Appreciable changes in the relative product yields were observed with the other nucleophiles, 
suggesting that they affected the reaction course at different stages and with different modalities. 
Thus, free DNA bases were more effective at inhibiting product formation from 4OHE than from 
2OHE. However, even in presence of a 4-fold excess of the nucleophiles, formation of products 9-
11 and 15 remained significant with the substrates at 10 µM concentration, and this would a fortiori 
be so at lower more physiological concentrations. In all cases, catechol estrogen consumption was 
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not affected by the additives, indicating that the inhibitory effects were indeed due to the trapping of 
oxidized intermediates.  
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Figure 14. Effect of various nucleophiles on the formation of compounds 9-11 and 15 by tyrosinase catalyzed 
oxidation of 2OHE and 4OHE, respectively. Percent of control + SD is reported. Nucleophiles (adenine (Ade), cytosine 
(Cyt), thymine (Thy), glutathione (Glu), 2-deoxyguanosine (2-dGua), imidazole (Imi)) were at 4-fold molar excess with 
respect to substrates at 60 mM. Compound 9: yellow bars; Compound 10: orange bars; Compound 11: red bars; 
Compound 15: deep red bars. 
 
Concluding remarks 
 
The results of this study have yielded further insights into the conversion pathways of the catechol 
estrogens 2OHE and 4OHE beyond the o-quinone stage. A battery of products have been isolated 
and spectrally characterized, for use as standards for the identification of novel estrogen 
metabolites.  
Although some of the products described here are not entirely unprecedented, as they have been 
previously reported as such or as their estrone analogs, to the best of our knowledge none of them 
has been obtained by tyrosinase-catalyzed oxidation of 17βE, nor by reaction of 17βE with other 
enzymes or chemical oxidants under biomimetic conditions. From the chemical viewpoint, the 
generation of product 10 by oxidation of 2OHE, and the formation of the novel dimer 14 by attack 
of 2OHE to the o-quinone of 10 appears to be of particular interest. 
The use of commercially available mushroom tyrosinase, though of questionable relevance to 
mammalian systems, was necessary for preparative scale reactions. This enzyme may yet be taken 
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as a convenient model of the tyrosinase-like activity described in uterine and estrogen responsive 
tissues, since it displays an efficient monophenol monooxygenase (cresolase) activity. Furthermore, 
most of the previous studies on the tyrosinase-estradiol interaction were performed with the 
mushroom enzyme.54, 78, 98 
While products 9, 11, 12 and 15 were formed by oxidation of the estrogens at nanomolar 
concentrations, products 10, 13 and 14 became detectable at substrate concentrations in the 
micromolar range. Thus, their formation may be implicated only under circumstances in which 
abnormally high concentrations of 17βE are present in settings of oxidative stress, e.g. during 
estrogen replacement therapy. In this connection, the finding that in the micromolar concentration 
range the 2,3-naphthoquinone from 10 can act as an efficient Michael acceptor toward the 3-OH 
hydroxyl function of 2OHE is biologically significant, as it may be taken to suggest that 2OHE can 
be converted to other reactive quinone intermediates in addition to CE-2,3-Q. 
Clearly, more studies are required before the new products can be ranked among estradiol 
metabolites, and their toxicity or DNA-binding properties have to be tested in comparison with 
catechol estrogens and the CEQs. These latter are commonly regarded as the ultimate carcinogenic 
species produced by the oxidative metabolism of estrogens via the catechol estrogen pathway; 
however, the results of this study raise the possibility that at low physiological concentrations the 
actual mechanisms of estrogen-induced DNA damage and toxicity may be more complex than 
implied by commonly accepted views centered only on CEQ formation.  
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CHAPTER II 
Oxidative Transformations of 17βE 
 
Beyond the specific relevance to the steroid sector, the oxidation of estrogen compounds represents 
an attractive research issue because of its potential as convenient entry to complex functionalized 
scaffolds of academic and industrial interest, e.g. in asymmetric synthesis99 and supramolecular 
chemistry,100 in the quest for innovative lead compounds in anticancer therapy,101 or for liquid 
crystal preparations,102 where 17βE and related compounds are commonly employed.   
Halogenated, oxy-functionalized and/or desaturated on steroidal backbone estrogenic derivates find 
interesting application in several fields so that simple and in good yield procedures for preparation 
of these compounds are useful to gram scale preparations.  
For example, in spite of considerable interest of catechol estrogens for toxicological studies and as 
starting materials for novel steroidal derivates with antiestrogenic properties, their availability is 
limited by the lack of a facile and expeditious preparative procedure.103 Classical approaches based 
on phenolic nitration involve at least three step and, for the synthesis of 2OHE and 4OHE, reductive 
conversion of the 17-oxo group of an estrone derivative.103c Moreover, protection/deprotection steps 
with cromatographic separations are often required. Use of potassium nitrosodisulfonate (FREMY’s 
salt) for the one-step chemical conversion of estrone/estradiol to a mixture of the corresponding 2,3- 
and 3,4-quinones had been reported earlier by Gelbke et al.103e The method involved a laborious 
work-up and ended up with very low overall yields of cathecol estrogens. 
Another class of estradiol-related compounds that have found application in estrogen replacement 
therapy, prevention, and treatment of osteoporosis,104 in the detection and treatment of hormone 
dependent tumors,105 or for the prevention and therapy of ophthalmic diseases106 are 10β-
substituted-17β-hydroxyestra-1,4-dien-3-ones. In addition, the identification of the 10-hydroxy 
derivative (p-quinol) in the redox cycling mechanisms underlying the putative antioxidant and 
cytoprotective properties of 17βE,107 suggested its employment as prodrug of antioxidants,108 while 
the 10β-halo-derivatives have been shown to be valuable tools for probing interactions at estrogen 
receptors.109 
A number of synthetic approaches to 10β-substituted-17β-hydroxyestra-1,4-dien-3-ones have been 
reported,110-113 but they often require manipulation of estrone and 17βE derivatives, lengthy 
protection/deprotection steps or functional group modifications, resulting in complex mixtures of 
products. The best procedures for preparation of p-quinol derivatives are below reported: in the 
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first, oxidation of 17βE with lead tetraacetate results in a 10% yield of the corresponding p-quinol 
acetate that is hydrolized by sodium metal in absolute methanol.111 
The second procedure involves oxidation of 17β-estradiol monoacetate with m-chloroperbenzoic 
acid and a catalytic amount of (BzO)2 for 1.5 hours under irradiation with a 60 W tungsten lamp 
leading to the product in 52% yield, along with an epoxy-derivative.114 Other procedures are also 
available that afford the desired product, but in lower yields. 
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Access routes to 10β-halo derivatives of 17βE have also been reported,115-117 though expensive 
organic chlorinating agents are employed and complex mixtures of products are usually obtained 
requiring separation and purification steps. For example, access to the 10β-chloro derivative 2 is 
based on the reaction of 17βE with 2,3,4,5,6,6-hexachloro-2,4-cyclohexadienone in DMF which 
affords the desired compound in ca 75% yield together with 25% of other chlorinated derivatives.117 
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An example of estradiol-related compounds that have found application in asymmetric synthesis are 
steroidal BINOL-type ligands. Axially chiral nonracemic binaphthyls have achieved an important 
place in asymmetric metal-catalyzed synthesis since it was shown that their diol or bis-posphine 
derivates can introduce high degrees of enantioselectivity in several chemical transformations, e.g. 
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the Ti-alkoxide mediated addition of R2Zn compounds to aldheydes, LiAlH4 reductions, carbonyl 
ene reactions, aldol additions, cyanohydrin formation or hydrogenation reactions.118-120 Therefore, 
the preparation of new chiral binaphthyl ligands is a subject of increasing interest and the 
development of a synthetic route making the BINOL-type ligands available in its diastereopure 
forms has achieved a significant place in asymmetric synthesis.   
Also halogenation of 17βE and generally of aromatic compounds is a highly useful reaction for 
providing precursors to a number of organometallic species of potential relevance in the synthesis 
of natural products and pharmaceutically important compounds121. For istance antiestrogen therapy 
is the most widely used endocrine manipulation for the treatment of breast cancer, especially in 
postmenopausal women. Unfortunately, the compounds presently available possess mixed 
agonistic/antagonistic activity, thus potentially limiting their therapeutic efficacy. Following the 
observations that halogenation of 17βE can increase the affinity of its binding (expressed as RBA) 
to the estrogen receptor, a series of new steroidal antiestrogens (an example is below reported) have 
been synthesized.122  
OH
X
OH
H
H H
 
Moreover aryl bromides and iodides are of importance in organic synthesis because of their utility 
to transition-metal-catalyzed cross coupling reactions to furnish complex functionality.123 Then, the 
alogens on aromatic rings have been used as potential protecting or blocking groups in synthetic 
organic chemistry thanks to reductive elimination of halogens.124, 125 In fact the 2- and 4-
haloestrogens are readily methoxylated to give the corresponding 2- and 4-methoxy derivates 
regiospecifically, that are used for treating neoplasm (such as lung neoplasm, breast neoplasm, 
melanoma, prostate neoplasm, pancreatic neoplasm, brain neoplasm).126 
Many established methods for the direct introduction of halogen atom into aromatic molecules have 
been reported.127 Aryl iodides are usually more difficult to prepare than the other corresponding aryl 
halides due to the low electrophilic strenght of iodine. Hence, synthetic methods involving a source 
of I+ as the reactive species seem to be the most convenient procedures for the direct iodination of 
arenes. Generally, arenes can be iodinated by iodine in the presence of a Lewis acid, a hydrogen 
iodide trap or most commonly in the presence of an oxidizing agent.128 
All these examples of steroidal derivates support their significance in applicative and academic 
fields and their preparation constitutes a synthetic intriguing challenge, as well as practical value. 
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Catechol estrogen preparation129 
 
As previously described, the catecholestrogens are important products of metabolic transformation 
of the estrogens arising by P450-mediated hydroxylation of 17βE and estrone, respectively, at the 
2- and 4-positions of the phenolic A-ring.130 Because of their implication in the mechanisms of 
estrogen-related carcinogenesis,131 as well as their  interest in toxicological studies and as starting 
materials for novel steroidal derivatives with antiestrogenic properties, a synthesis on preparative 
scale is necessary.  
In connection with our studies on the oxidation of estrogens, we have developed a simple and 
convenient one-pot procedure for the preparation of the catecholestrogens of 17βE and estrone, 
which involves use of the hypervalent iodine (V) reagent o-iodoxybenzoic acid (IBX)132 under 
carefully controlled reaction and work-up conditions. Despite its early description (1893),133 IBX 
languished, essentially forgotten, until the 1980s when the seminal works of Dess and Martin 
initiated a renaissance in interest in the chemistry of hypervalent iodine(V) reagents.134 Within the 
past decade, the use of IBX as a reagent has grown dramatically, a surge driven by an improved 
method for its synthesis,132 and by explorations into its chemistry that have unveiled its versatility in 
mediating a wide array of transformations with far-reaching synthetic applicability. In particular, 
investigations have revealed that IBX is a powerful single electron-transfer (SET) agent that readily 
accepts new heteroatom-based ligands and, thus, can 1) effect the oxidation of ketones, aldehydes, 
and silyl enol ethers to the corresponding α,β-unsaturated carbonyl compounds,135-137 2) oxidize 
benzylic positions,135 3) facilitate the cyclization of N-aryl amides, (thio)carbamates, and ureas to 
afford various heterocycles and amino sugars,138-141 and 4) convert monophenol to o-quinones.142 In 
light of this last potential, we have developed an IBX-mediated o-hydroxilation of estrogens. 
In a typical procedure, solid IBX was added to a solution of 17βE or estrone (16) in CHCl3/MeOH 
mixture at -25 °C. After 24 h methanolic NaBH4 was then added at -25 °C under vigorous stirring 
and NaBH4 excess was removed by a mild acidification with acetic acid. The mixture was washed 
with saturated NaCl solution containing 10% sodium dithionite buffered at pH 7.0 with sodium 
phosphate. The two catechol estrogens were separated by preparative TLC.  
This procedure differs from previous IBX-mediated oxidations142-144 in that the key steps are run in 
the cold, to prevent quinone conversion to intractable materials in the chloroform-containing 
medium,85 and the critical reductive treatment is efficiently carried out with methanolic NaBH4 
under homogeneous phase conditions. The latter treatment allowed product recovery in good-to-
high yields, without affecting the carbonyl at C-17 of estrone substrates 17 and 18. Chemoselective 
reduction of the quinone moiety, sparing the carbonyl function of 17 and 18, was made possible by 
the low temperature maintained during NaBH4 treatment and the cold acid quenching of the 
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mixture; partial reduction occurred when the treatment was performed at room temperature and/or 
the cold acid quenching step was omitted prior to solvent evaporation. 
For comparative purposes, and to assess its potential and scope for phenolic oxidation, the 
procedure was extended to a number of representative substrates. These included the parent phenol 
(19), 3,4-dimethylphenol (20), 2,5-dimethylphenol (21), 1-naphthol (22), 2-naphthol (23), 8-
hydroxyquinoline (24), and 2-tert-butylphenol (25). Reaction conditions, products and yields are 
provided in Table 1. 
The reaction proceeded smoothly with complete substrate consumption in all cases and resulted in 
good to-high product yields. Data in Table 1 indicate that the reaction allows for the regioselective 
conversion of monophenols to o-diphenols (catechols), and that in few cases, that is, 17βE, estrone, 
and 20, two ortho regioisomers are produced in comparable yields. This is a reflection of the 
comparable steric hindrance and reactivity on the two positions ortho to the OH group. The IBX-
induced conversion of phenol to catechol with a brief mechanistic description142,143 is illustrated in 
Scheme 3.  
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Scheme 3. Proposed mechanism of o-hydroxilation/oxidation of phenol 
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Substrate 
Concn 
(mM)/IBX 
equiv 
Solvent 
Reaction 
time 
Product(s)/yield(s)(%) 
OH
OH
H
H H
17bE
 
20/2.5 
CHCl3/MeOH 
3/2 
24 h 
OH
OH
H
H H
OH
2OHE
42a 49b
OH
OH
H
H H
OH 4OHE
44a 48b
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H
H H
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20/2.5 
CHCl3/MeOH 
3/2 
24 h 
OH
O
H
H H
OH
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45a 50b OH
O
H
H H
OH 18
47a 48b
 
OH
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90/2.0 
 
CHCl3/MeOH 
4/1 
20 min 
OH
OH
97b
 
OH
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100/1.5 CHCl3 12 h 
OH
OH
38a 45b
OH
OH
35a 40b
 
OH
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100/1.5 CHCl3 12 h OH
OH 49a
 
OH
22
 
70/1.5 CHCl3 12 h 
OH
OH
96b
 
OH
23
 
70/1.5 CHCl3 12 h 
OH
OH
90b
 
N
OH 24
 
60/2.0 
 
CHCl3/MeOH 
4/1 
1 h N
OH
OH
60a
 
OH
25
 
60/2.0 
 
CHCl3/MeOH 
4/1 
1 h 
OH
OH
65a
 
a
 Determined on products isolated by TLC on silica (impurities below 1HNMR detection limits)  
b
 Formation yield (determined by HPLC by comparing peak area with external calibration curves) 
Table 1. IBX-promoted o-hydroxylation of estrogens and other phenols Table 1. IBX-promoted o-hydroxylation of estrogens and other phenols Table 1. IBX-promoted o-hydroxylation of estrogens and other phenols 
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Use of cold methanolic NaBH4 after oxidation of phenols 19–25 proved to be critical for efficient 
quinone reduction since, with CHCl3 or a CHCl3/MeOH mixture as the solvent, a simple reductive 
work-up with sodium dithionite at room temperature143 was not entirely satisfactory leading in some 
cases to a poor recovery of the catechol products. In a previous paper144 Quideau et al. Reported 
oxidation of 2,5-dimethylphenol (21) with Stabilized IBX (SIBX), a non-explosive alternative to 
IBX, in THF to give as main product a dimeric species arising from hydroxylation at the carbon 
bearing the methyl group. We did not notice the presence of that dimer in our mixture, so it is likely 
that the different regioselectivity observed in the present study reflects the change of solvent and/or 
temperature favoring attack of the oxygen to the unsubstituted position of the aromatic ring. The 
potential of IBX for the conversion of phenols to o-quinones and catechols was also underscored in 
a recent paper,142 in which a number of phenols substituted with electron-donating groups were 
shown to undergo regioselective oxidation. The procedure described herein not only stands 
comparison with the previous one, as judged from the reported oxidation of 23 in CDCl3,142 but 
expands its scope to include the estrogens and several other phenolic compounds. Particularly 
worthy of note is the conversion in good yield of phenol itself, for which the IBX-mediated 
hydroxylation was reported to be unsuccessful.142 
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10β-substituted 17β-hydroxyestra-1,4-dien-3-ones preparation145 
 
As part of our studies toward the preparation of functionalized steroidal scaffolds of potential 
investigative value and/or to be evaluated as pharmaceutical agents, we have developed 
operationally simple and convenient procedures for the one-pot conversion of 17βE to 10β,17β-
dihydroxyestra-1,4-dien-3-one (26) and 10β−chloro-17β-hydroxyestra-1,4-dien-3-one (27).  
 
Several oxidants, such as potassium permanganate, lead tetraacetate, diacetoxyiodobenzene, sodium 
periodate, potassium persulfate were tested for their ability to bring about direct conversion of 17βE 
to the quinol 26. Of these, potassium permanganate proved to be the most efficient in producing the 
desired quinol in good yield. The reaction was investigated under different experimental conditions, 
and an optimized procedure was eventually developed, using a acidic water/ethyl acetate 1:1 as 
solvent and 2 molar equivalents of the oxidant. By this method, complete substrate consumption 
was observed in less than one minute, and the desired quinol 26 was obtained in 75% isolated yield 
in pure form in the organic phase. Product identity was determined by spectral analysis and 
comparison with literature data; the stereochemistry of the C-10 centre was confirmed from the CD 
spectrum146 showing a negative Cotton effect (figure 15) similar to that reported for 10β-substituted 
compounds.117, 146-148 
To the best of our knowledge, this is the first method 
for preparing 26 by direct oxidation of 17βE without 
functional group protection and chromatographic 
separation. 
10β-Chloro-17β-hydroxyestra-1,4-dien-3-one (27) 
was prepared in 44% isolated yield (48% formation 
yield as determined by HPLC) by treating 17βE with 
2 molar equivalents of NaClO2. After 30 min, substrate 
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Fig.15: CD spectrum of compound 26 
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consumption was complete, and compound 27 was obtained by extraction of the mixture with ethyl 
acetate, followed by chromatographic purification. Configuration at C-10 was determined by CD 
analysis.117 Under these reaction conditions no formation of 26 was observed.  
For both products 26 and 27 complete resonances 
assignment including identification of β protons 
(Table 2) was obtained by 2D (COSY, HMQC, 
HMBC, and ROESY) NMR analysis. Coupling 
costants (Table 3) were obtained by DQF-COSY 
experiments. 
Careful analysis of the reaction mixture of 17βE 
with NaClO2 revealed the presence of minor 
components which were purified by preparative 
TLC and subjected to complete spectral analysis. 
The most polar compound was characterized as 
the novel 4-chloro-10β,17β-dihydroxyestra-1,4-
dien-3-one (28). The CD spectrum supporting the 
assignment of configuration at C-10 is shown in 
figure 17. The other two products were identified 
as 2,10β-dichloro-17β-hydroxyestra-1,4-dien-3-
one (29), and 4,10β-dichloro-17β-hydroxyestra-1,4-dien-3-one (30) previously obtained by 
chlorination of 17βE with N-chloro imide reagents.117 
 
 
 
 
 
 
The procedures here disclosed for the preparation of the 10β-substituted 17β-hydroxyestra-1,4-
dien-3-ones 26 and 27 are amenable to gram scale preparations and represent valuable alternatives 
to previous methodologies because of the lack of protection/deprotection steps, simple work-up, and 
use of cheap, non-toxic reagents.  
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Fig. 16: CD spectrum of compound 27 
     Fig. 17: CD spectrum of compound 3 
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Table 2. Selected NMR data for compounds 26-27a  
 26 27 
 δC  δH  δC  δH  
C-1 151.1 6.98 147.9 7.13 
C-2 131.3 6.34 126.6 6.18 
C-3 186.0 - 185.0 - 
C-4 126.1 6.17 123.8 6.06 
C-5 165.2 - 161.1 - 
C-6 32.3 2.45 (β), 2.33 32.3 2.85 (β), 2.41 
C-7 33.4 1.95 (β), 1.06 32.3 1.96 (β), 1.03 
C-8 35.1 1.97 35.8 1.96 
C-9 55.6 1.20 53.4 1.34 
C-10 76.3 - 67.7 - 
C-11 22.7 1.83 (β), 1.68  22.9 1.89 (β), 1.80  
C-12 36.3 1.99 (β), 1.05 35.9 1.91 (β), 1.12 
C-13 43.2 - 43.0 - 
C-14 49.9 0.92 49.4 1.02 
C-15 23.6 1.33 (β), 1.62 23.5 1.38 (β), 1.61  
C-16 30.4 1.45 (β), 2.04  30.4 1.50 (β), 2.09  
C-17 81.6 3.65 81.4 3.65 
C-18 11.0 0.83 11.0 0.85 
a
 spectra were taken in CDCl3. 
 
 
 
 
 
 
 
 
Table 3. J(H,H) absolute values (Hz) 
Atoms 26 27 
1,2 10.4 10.4 
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2,4 2.0 2.0 
4,6β 1.7 1.6 
6α,6β 13.2 13.2 
6α,7α 4.4 4.4 
6α,7β 2.6 2.4 
6β,7α 13.4 13.6 
6β,7β 4.4 4.8 
7α,7β 13.0 12.0 
7α,8β 11.2 11.2 
7β,8β n.d. n.d. 
8β,9α 12.9 12.0 
8β,14α 10.8 11.0 
9, 11α 4.0 4.8 
9, 11β 11.6 n.d. 
11α,11β 13.2 13.2 
11α,12α 4.5 4.5 
11α,12β 2.2 2.0 
11β,12α 12.0 12.0 
11β,12β n.d. 4.4 
12α,12β 13.4 11.2 
14α,15α 7.4 6.8 
14α,15β 12.5 11.6 
15α,15β 11.8 11.6 
15α,16α 10.2 8.8 
15α,16β 3.4 3.6 
15β,16α 5.4 5.6 
15β,16β 11.4 12.0 
16α,16β 12.9 9.2 
17α,16α 8.6 7.6 
17α,16β 8.3 8.0 
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Halogenation of 17βE 
 
In connection with our ongoing program on NaClO2 mediated oxidations of 17βE, we envisioned a 
simple route, which might involve iodination of 17βE to give 2-, 4-iodoestradiol and 2,4-
diiodoestradiol (31, 32 and 33 respectively). The iodination involves use of NaI as the iodine source 
that is added to NaClO2 reaction mixture. Although the mechanism for this iodination and for other 
methods reported in literature is uncertain, it is proposed that the oxidation of an iodide anion 
results in the in situ formation of an electrophilic iodonium species (I+), which is responsible for 
iodination of the aromatic nucleus.149 Regulation of the equivalents of the iodinating reagents allows 
to select 31, 32 and 33. So iodination of 17βE with NaClO2/NaI at the equivalents ratio of 0.5/0.5 
gives 31 with no total substrate consumption. Using NaClO2/NaI 4/8, TLC analysis of the reaction 
confirms the formation of 32 and 33 in the ratio of 1/1 with complete conversion of substrate. 
 
 
 
 
 
To establish the scope and potential of the methodology, a variety of representative aromatic 
compounds have been subjected to nuclear iodination and the results are shown in Table 4. 
The peculiarity of procedure consists in total consumption of substrate and complete conversion to 
only iodinated product, as demonstrated by NMR and mass spectroscopy analysis. Moreover, the 
reagents reported for iodination of aromatic substrates include N-iodosuccinimide,150 I2-mercury 
salts,151 I2-nitrogen dioxide,152 I2-chromium oxide,153 iodine monochloride,154 NaOCl-NaI,155 NH4I-
oxone®,156 and most of these reagents are complicated, costly or use-toxic heavy metal catalysts 
with potential environmental problems due to the generation of hazardous waste. So a quick, 
inexpensive, easy and environmentally benign method for iodination is looked-for and this 
procedure has such features. Also, by this methodology 3-iodo-5-nitroindole has been obtained with 
good yield and this is worthy of note because is the first preparation reported in the literature. 
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Substrate Concn (mM) 
NaClO2 eq/NaI eq 
Reaction 
time Product 
Yield 
(%) 
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Table 4. Iodination of selected phenols by NaClO2/NaI method 
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A possible mechanism of this iodination technique is based on capability of NaClO2 to oxidize 
iodide anion in presence of acid to liberate I2. At the same time ClO2- is reduced to Cl2 and, 
according to a reported hypothesis,128 iodine monochloride, presumably formed from the liberated 
halogens, may act as the electrophile.  
HClO2 + 3I- + 3H+ → 1/2 Cl2 + 3/2 I2 + 2 H2O 
Cl2 + I2 → 2 ICl  
ICl + substrate → iodinated substrate  
In view of standard reduction potential of ClO2-/Cl2 and I-/I2, the mechanism outlined above is 
likely from electrochemical point of view. 
HClO2 + 3H+ + 3e- → ½ Cl2 + H2O               E°(V) 1.628 
½ I2 + e- → I- E°(V) 0.5355 
During iodination experiments it was added NaBr instead of NaI and bromination of estradiol ring 
A was noted. Reaction conditions are identical to iodination procedure and also in that case 
modulation of brominating reagents allows to select mono- and dibromination. In particular reaction 
of 17βE with NaClO2/NaBr in the equivalents ratio of 0.5/0.5 gives 2-bromoestradiol (34) and no 
total substrate consumption. Using NaClO2/NaBr 2/4, TLC analysis of the reaction confirms the 
formation of 2,4-dibromoestradiol (35) and 2,4-dibromoestrone (36) with complete conversion of 
substrate.  
 
 
 
 
 
 
 
 
Another method of estradiol bromination has been performed by the use of NaBrO3 combined with 
a reducing reagent such as Na2S2O4. This coupling serves as an effective bromohydroxylation 
reagent of olefins,157 alkynes, and allylic alcohols158 and an oxidizing agent of primary alcohols,159 
diols, and ethers.160 Moreover the NaBrO3/Na2S2O4 reagent in organic synthesis facilitates the R-
bromination of alkylbenzenes under a two-phase system using ethyl acetate as solvent under 
ambient conditions.161 This procedure has never been applied to phenolic substrates, so we have 
used this reagent to obtain, possibly, brominated estradiol. 
Owing to the difficulty of isolating any brominating species derived from NaBrO3/ Na2S2O4 reagent 
in AcOEt/H2O and the complexity of the reaction medium employing the two-phase system, it 
seems rather hazardous to make an accurate assessment about the nature of the brominating species 
involved in this reaction. However, Kikuchi et al.161 have made several proposals, which seem to 
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agree with their experimental results. The reaction is initiated by the generation of HOBr from 
NaBrO3/ Na2S2O4 in the aqueous phase, and then the resulting HOBr is thought to decompose 
gradually in aqueous solution with liberation of Br• or a Br• equivalent, which moves from the 
aqueous phase to the ethyl acetate phase, in which the substrate is dissolved. As a consequence, the 
bromination of 17βE takes place.  
To a two-phase system comprised of ethyl acetate involving 17βE and aqueous NaBrO3 (30 equiv) 
was added dropwise aqueous Na2S2O4 (30 equiv) over a period of about 15 min under stirring and 
the mixture was allowed to react at room temperature for 4 h. The reaction produced 3-hydroxy-
2,4,10-tribromo-9,10-secoestra-1(10),2,4-trien-9-one (37) along with 2,4-dibromoestrone (38). 
 
The proposed mechanism of secoestra-derivate formation is outlined in scheme 4 and involves 
oxidation of 17βE to quinone methide by Br•, formation of bridged bromonium ion and B ring 
opening by hydroxide ion. 
Besides the general pharmaceutical use of halogenated derivates of estrogens, the halogenated 
secosteroidal compounds have been shown to be potential estrogen receptor-based imaging agents 
for human breast tumors.162 
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Scheme 4. Schematic outline of the proposed mechanism of formation of product 37 
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OXIDATION OF 17βE IN SOLVENT FREE 
 
Solvent free conditions have been employed in oxidation reactions of 17βE to obtain steroidal 
derivates by simple, eco-friendly and good-to-high yielding procedures. In fact solvent removal 
reduces environmental impact and inserts the processes in the green chemistry that is aimed to 
development of eco-compatible synthetic methodologies. Moreover solid phase procedure allows of 
simple work-up of reaction mixture and removes solubility problems of 17βE in basic and acid 
conditions. 
Optimized sperimental procedure for preparation and work-up of reaction mixture is below 
reported: 
1. a mixture of substrate and oxidant is finely powdered in agate mortar and pestle; 
2. the mixture is put in a test tube and kept at elevated temperature for variable time intervals.  
3. when substrate consumption is complete (TLC evidence), the mixture is diluted with water, 
acidified and extracted with ethyl acetate; 
4. if necessary, the crude mixture is subjected to chromatographic purification. 
Among the tested chemical oxidants, FeCl3 and FeNH4(SO4)2 have provided interesting results.  
In both of the oxidants, solid phase conditions have been optimized varying the temperature, the 
reaction time and the oxidant equivalents to improve substrate conversion and reaction yields. 
 
Reaction with FeNH4(SO4)2 
 
The oxidation of 17βE is carried out with 2 equivalents of FeNH4(SO4)2 for 6 h at 150 °C and gives 
a principal product identified as 3’-methyl-7-hydroxy-1,2-cyclopentenophenanthrene (39) on basis 
of spectral analysis. Pseudo-molecular ion peak at m/z 247 (ESI(-)MS) is an indication of molecular 
dehydration and dehydrogenation. 1H NMR shows in the aromatic region seven signals (four 
doublets and an ABX system) and five, as well as methyl signal, in the aliphatic region. The scalar 
contact of methyl signal with H17 and the shift of this proton from 3.60 to 3.40 ppm provides 
support to the methyl migration together with the desaturation of rings B and D to afford a 
phenanthrene system. 
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     39
  
This is the first reported isolation of this compound, being the sole related compound described in 
the literature some derivates functionalized by alkyl groups on phenolic oxygen. For example, 3’-
methyl-7-methoxy-1,2-cyclopentenophenantrene was obtained heating methylated estradiol, 3-
methoxy-estra-1, 3 ,5 (10)-trien-17β-ol, with 78% (w/w) sulphuric acid for 20 minutes at 100 °C.163 
The reaction mixture required then separation and purification step. By the solvent free procedure, 
instead, complete substrate consumption is observed and the aromatised and dehydrated product is 
obtained in 67 % isolated yield in pure form. 
The hypothized mechanism, outlined in scheme 5, involves dehydrogenation without opening of D 
ring, dehydration, methyl migration with tertiary carbocation formation and proton extraction to 
obtain cyclopentaphenanthrene. This hypothesis derives from isolation of a naphtalenic 
intermediate  after 3 hours of reaction.  
The stereochemistry of C17 is not well defined, the measurement of optical rotatory 
power [ ] nmC58925°α =0.016° supports a racemic mixture proposal. 
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Scheme 5. Schematic outline of the proposed mechanism of formation of products 39 
 
The cyclopenta[a]phenanthrenic derivates of 17βE are considered potential anticholesteremic and  
hypolipidemic agents, in fact in vivo experiments have shown a significant plasma cholesterol 
lowering in hypercholesteremic rats treated with these compounds.164  
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Reaction with FeCl3 
 
The oxidation of 17βE is carried out with 8 equivalents of FeCl3 for 6 h at 60 °C and gives two 
main products, not known in the literature, obtained through PLC fractionation. The mass and NMR 
data led to straightforward formulation of desaturated and chlorinated species, in particular a 
monomer (4,15-dichloroestra-1,3,5(10)-trien-3,17β-diol) (40) and a C2-symmetric 4,4’ dimer (4,4’-
di[15-chloroestra-1,3,5(10)-trien-3,17β-diol]) (41) 
 
In fact, the monomer exhibits pseudo-molecular ion peak at m/z 333 (ESI(-)MS) and two peaks at 
335 [M+2], 337 [M+4] in a ratio 100: 65: 12, indicating two chlorine atoms presence. The dimer 
shows pseudo-molecular ion peak at m/z 597 (ESI(-)MS) with an isotopic pattern like monomer. 
Moreover the two products show nearly identical 1H NMR spectra featuring in the aromatic region 
four doublets and in the aliphatic region six multiplets as well as methyl and H17 signals. 
The dimer is a very interesting compound because of its bissteroidal BINOL-type structure. BINOL 
and BINAP, which are employed in numerous catalytic and stoichiometric asymmetric reactions, 
and have attracted great attention over the last several years as ligands with C2-symmetry. 
Nevertheless there are at least two drawbacks for these compounds. The enantiomers of BINOL 
and/or BINAP have to be separated by 1) transforming the racemic compounds into 
diastereoisomeric derivatives; 2) separation of these derivatives; and 3) retransformation into 
BINOL or BINAP.165 Therefore the development of a synthetic approach making the BINOL-type 
ligands available in their diastereopure forms is a subject of increasing interest.  
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It is possible to hypothesize diastereoselectivity of this reaction leading to the chlorinated dimer on 
basis of collected data and on previous knowledge of rotational isomers of estradiol dimers,62 but a 
crystallographic analysis could resolve any doubts.  
The dimer exhibits two asymmetric centers (C13 and C17) in every unit and an axially chiral center 
at the biphenyl linkage, so the two possible rotational isomers are diastereoisomers. Hence their 
physical and chemical properties have to be different. Indeed HPLC, TLC, NMR analysis of 
chromatographic band do not evidence the presence of two species. Furthermore no appreciable 
interconversion of the rotamers is observed by heating to 180°C at which temperature the product 
begins to decompose significantly as previously shown for C2-symmetric 4,4’ dimer [cfr. page 15]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 52 
CONCLUSIONS 
 
 
In this work estrogen oxidative chemistry has been studied addressing two main issues: the 
elucidation of the molecular mechanisms of neuro- and cytoprotection as well as carcinogenic 
activities that 17βE exerts in several biological compartments; the exploitation of oxidative 
transformations as access routes to new steroidal scaffolds of potential biomedical and 
pharmaceutical relevance.  
So the work may be ideally divided in two section: experiments carried out under biomimetic 
conditions to examine 17βE biological activity related to its redox properties; and experiments 
using oxidative transformation as preparative tools for new steroidal derivates or of compounds 
well known in literature and already used.   
If the it is true the redox behaviour of 17βE may be considered the key of its cytoprotective 
activity46, 47 it is also that the same reactivity is involved in estrogenic induced carcinogenesis.55, 56, 
57
 According to literature cytoprotection is essentially ascribed to an antioxidant activity showed by 
17βE under oxidative stress condition46,47 while formation of highly reactive oxidation derivatives 
of 17βE (i.e. 2- and 4-hydroxyestradiol) plays a pivotal role in the molecular mechanism of 
estrogen carcinogenesis associated to an alteration of cellular redox homeostasis in the tissues with 
high levels of estrogens (ovary, uterus…). In fact 17βE is metabolised in vivo to catechols, which 
are then oxidized to redox active/eletrophilic o-quinones that could initiate the carcinogenic process 
by binding to DNA and depurination processes.57 
On the other and new steroidal derivatives based on 17βE modification appears to be promising and 
sometimes effective scaffold for a wide range of application form pharmaceutical to high tech 
fields. In this prospective oxidative chemistry may be an innovative access tool to unprecedented 
estradiol functionalized derivatives often difficult if not impossible to get by tradition synthetic 
approach.  
 
In this double frame the first issue was addressed carrying out biomimetic oxidation in aqueous 
phosphate buffers using as oxidants the enzyme systems peroxidase/H2O2 and tyrosinase/O2, both 
evidencing the susceptibility of 17βE to oxidation in such conditions.  
In fact a substantial substrate consumption was observed with the peroxidase/H2O2 system, with 
formation of a number of products whose chromatographic and spectral properties were suggestive 
of oligomer species. In particular five dimers and three trimers have been isolated and in the case of 
the trimers and a dimer is the first isolation reported in the literature. The coupling involves the only 
A ring trough the formation of biphenyl and ether-biphenyl linkage. In all C-coupling products 
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involving C4, the sterically hindered biphenyl linkage represents a stereogenic element, which adds 
to those already present in 17βE. For all isolated products featuring such structural system, 
configuration at the biphenyl linkage (and thus absolute stereochemistry) was established by the 
exciton chirality method on the basis of the Cotton effect, and interconversion energy was also 
determined by dynamic NMR. Overall this study confirms 17βE antioxidant properties and 
provides coupling products of 17βE that lay the foundation for the future studies aimed to develop 
novel estrogen derivatives based on oligomeric scaffolds.  
 
17βE oxidative transformations induced by tyrosinase/O2 have also been investigated on the base of 
putative molecular mechanism underling carcinogenesis induction. Tyrosinase is the key enzyme of 
melanogenesis in epidermal melanocytes72 and possesses both monophenol monooxygenase activity 
(EC 1.14.18.1, tyrosine, 3,4-dihydroxyphenylalanine:oxygen oxidoreductase) and o-
diphenoloxidase activity (EC 1.10.3.1, o-diphenol:oxygen oxidoreductase). Tyrosinase-like proteins 
have recently been identified in estrogen-responsive tissues as well as in the nervous system.74-76 
Such enzymes from nuclear extracts were found to possess both cresolase and catecholase activity, 
as well as estrogen binding properties, and may thus play a role in the conversion of 17βE into its 
hydroxylated metabolites.  
Mushroom tyrosinase was selected as a convenient oxidizing system for producing CEQs from 
17βE and for monitoring their fate under physiologically relevant conditions. At variance with the 
mammalian enzyme from melanoma cells,77-79  which is apparently unable to induce estradiol 
hydroxylation, mushroom tyrosinase displays efficient cresolase activity toward this estrogen and is 
highly effective in causing catechol estrogen oxidation to CEQs.  
The reaction of 17βE with the tyrosinase/O2 system was examined with substrate concentration in 
the range 1nM-30µM in phosphate buffer at pH 7.4. HPLC analysis of the ethyl acetate-extractable 
fraction the oxidation mixture evidenced a complex reaction pathway including the presence of the 
catechol estrogens 2OHE and 4OHE along with a series of species with mass spectra suggestive of 
transformation products of 2OHE and 4OHE. The main peaks were isolated by preparative HPLC 
and were characterized by extensive 2D NMR and mass spectrometric analysis. The same products, 
with more high yields, have been obtained by the tyrosinase-catalyzed oxidation of 2OHE and 
4OHE prepared by a simple and convenient one-pot procedure developed ad hoc and involving 
phenol IBX-mediated o-hydroxilation.129 Hence these observations have made easier products 
isolation on a preparative scale and have evidenced tyrosinase capability to hydroxilate 17βE and to 
oxidize CE, generating species that result from o-quinones. Some products, and in particular the 
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naphtalenic one, have been difficulty isolated because they easy react with CE to give dimeric 
species. 
To test potential significance of this 17βE oxidative pathway, the effects of some nucleophilic 
compounds on the oxidation of the catechol estrogens were investigated. Selected nucleophiles 
included adenine,94 thymine,95 cytosine,95 2-deoxyguanosine,80 imidazole83 and glutathione96, 97 for 
which the ability to trap CEQs was established. The data indicated that with both catechol 
estrogens, glutathione was by the far the most effective inhibitor of product formation, due likely to 
the ability of thiols to cause quinone reduction and/or trapping.96 
Appreciable changes in the relative product yields were observed with the other nucleophiles, 
suggesting that they affected the reaction course at different stages and with different modalities. 
Thus, free DNA bases were more effective at inhibiting product formation from 4OHE than from 
2OHE. However, even in presence of a 4-fold excess of the nucleophiles, formation of products 9-
11 and 15 remained significant with the substrates at 10 µM concentration, and this would a fortiori 
be so at lower more physiological concentrations. In all cases, catechol estrogen consumption was 
not affected by the additives, indicating that the inhibitory effects were indeed due to the trapping of 
oxidized intermediates. The results yield further insights into the conversion pathways of the CEs 
beyond the o-quinone stage and the isolated products could potentially be able to interact with 
biological macromolecules. So cytotoxicity mechanism of estogens could be more complex than 
commonly accepted one and based on adducts of estrogen o-quinones with DNA or proteins.  
 
In connection with the second issues, use of oxidative transformations as access routes to new 
steroidal scaffolds, a number of different oxidants and/or halogenating agents as well as reaction 
medium were exploited including aqueous, organic, biphasic and solvent free conditions.  
Indeed halogenated, oxy-functionalized and/or desaturated on steroidal backbone estrogenic 
derivates find interesting application in several fields and simple and in good yield preparation 
procedures are useful to gram scale preparations.  
Valuable results are obtained through preparation of 10β-substituted-17β-hydroxyestra-1,4-dien-3-
ones, class of estradiol-related compounds that have found application in estrogen replacement 
therapy, prevention, and treatment of osteoporosis,104 in the detection and treatment of hormone 
dependent tumors,105 or for the prevention and therapy of ophthalmic diseases.106 10β-hydroxy- and 
10β-chloroderivate were prepared. The former, also defined p-quinol, was produced by KMnO4 
(2eq) using an acidic water/ethyl acetate 1:1 as solvent. By this method, complete substrate 
consumption was observed in less than one minute, and the desired quinol  was obtained in 75% 
isolated yield in pure form in the organic phase. The stereochemistry of the C-10 centre was 
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confirmed from the CD spectrum146 showing a negative Cotton effect similar to that reported for 
10β-substituted compounds.117, 146-148 This one-pot procedure represents an alternative to previous 
methodologies because of the lack of protection/deprotection steps, simple work-up, and use of 
cheap, non-toxic reagents. In addition, the identification of the p-quinol in the redox cycling 
mechanisms underlying the putative antioxidant and cytoprotective properties of 17βE,107 suggested 
its employment as prodrug of antioxidants,108 while the 10β-halo-derivatives have been shown to be 
valuable tools for probing interactions at estrogen receptors.109 10β-Chloro-17β-hydroxyestra-1,4-
dien-3-one was prepared by treating 17βE with 2 molar equivalents of NaClO2 in acidic aqueous 
methanol. Also in this case, the procedure represents an alternative to previous methodologies 
involving expensive organic chlorinating agents and separation and purification of complex reaction 
mixture. 
Introducing NaI in NaClO2 reaction mixture, was obtained a practical and versatile estradiol 
iodination method. In particular, varying NaClO2 and NaI equivalents was possible to chemioselect 
iodination position on estradiol A ring. To establish the scope and potential of the methodology, a 
variety of representative aromatic compounds have been subjected to nuclear iodination and it was 
resulted rapid and chemioselective. Halogenations of 17βE and generally of aromatic compounds 
are highly useful reactions for providing the precursors to a number of organometallic species 
applicable in the synthesis of natural products and pharmaceutically important compounds. 121 Aryl 
iodides are usually more difficult to prepare than the other corresponding aryl halides due to the low 
electrophilic strenght of iodine. Generally, arenes can be iodinated by iodine or iodide in the 
presence of complex, expensive, toxic organic oxidizing agents. This method, indeed, requires 
cheap, non-toxic reagent and eco-friendly reaction conditions. 
Substituting anion with Br− was obtained a simple and cheap bromination method of estradiol 
phenolic ring and also in this case varying NaClO2 and NaBr equivalents is possible to chemioselect 
brominated product. 
Solvent free conditions have been employed in oxidation reactions of 17βE to obtain steroidal 
derivates by simple, eco-friendly and good-to-high yielding procedures. In fact solvent removal 
reduces environment impact and inserts the processes in the green chemistry that is based on 
development of eco-compatible synthetic methodologies. Among the tested chemical oxidants, 
FeCl3 and FeNH4(SO4)2 have provided interesting results.  
The oxidation of 17βE by FeCl3 (8 eq for 6 h at 60 °C) gives two principal desaturated and 
chlorinated products, not known in literature. The mass and NMR data are suggestive of a monomer 
dichlorinated in C4 and C15 and a C2-symmetric 4,4’ dimer totally conjugated. The dimer is a very 
interesting compound because of its bissteroidal BINOL-type structure which are employed in 
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numerous catalytic and stoichiometric asymmetric reactions as chiral ligands and auxiliares with 
C2-symmetry. The reaction peculiarity is the interesting yield (25%) and the elevated 
stereoselectivity that avoids laborious steps of derivativation and retransformation associated with 
separation of stereoisomers mixture.  
In the case of FeNH4(SO4)2, the oxidation of 17βE is carried out with 2 equivalents of oxidant for 6 
h at 150 °C and gives a principal product characterized by methyl migration in position 17, OH 
leaving and B and C ring aromatisation. This solvent free procedure allows to obtain one-pot 
aromatisation of two condensed rings and represents an alternative to the literature methodologies 
requiring harsh oxidation conditions as well as purification steps. 
In summary, main results afforded by the study here reported are may bee collected under this tree 
point: 
1. isolation of new estradiol-related species; 
2. thorough examination of potential metabolic pathways of estrogens oxidation in vivo; 
3. development of synthetic strategies for steroidal derivates and aromatic compounds; 
highlighting both the relevance of oxidative chemistry of 17βE to biological processes and the 
potential of oxidative transformations in the search and synthesis of new derivative of applicative 
interest.  
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Experimental Section 
 
 
General Methods. 17β-Estradiol (17βE), manganese (IV) dioxide activated 5 µm (85%), hydrogen 
peroxide (30% w/w solution in water), glutathione, 2-deoxyguanosine, cytosine, tymine , adenine, 
imidazole, 2-iodobenzoic acid, oxone (2 KHSO5-KHSO4-K2SO4), sodium borohydride, sodium 
dithionite, potassium permanganate, sodium chlorite, sodium iodide, sodium bromide, phenol, 3,4-
dimethylphenol, 2,5-dimethylphenol, 1-naphtol, 2-naphtol, 8-hydroxyquinoline, 2-tert-butylphenol 
were from Aldrich Chemie. Horseradish peroxidase (donor:H2O2 oxidoreductase; EC 1.11.1.7) type 
II and mushroom tyrosinase (EC 1.14.18.1) and tropolone were from Sigma. O-Iodoxybenzoic acid 
(IBX) was freshly prepared from 2-iodobenzoic acid according to a reported procedure.132  
Melting points were obtained with a Gallenkamp apparatus. Elemental analyses were performed 
with a Perkin-Elmer CHN analyzer mod. 2400. Ultraviolet spectra were performed using a diode 
array Hewlett Packard spectrophotometer model 8453E. CD spectra were taken on 
Spectropolarimeter Jasco J-715 at 25 °C using solutions of the products in ethanol exhibiting 
absorbance values in the range 0.1–0.2 at 220 nm. 1H (13C) NMR spectra were recorded at 400.1 
(100.6) MHz using a Bruker DRX–400MHz instrument fitted with a 5mm 1H broadband gradient 
probe with inverse geometry. 1H,1H Correlation spectroscopy (COSY), 1H,13C heteronuclear 
multiple quantum coherence (HMQC), 1H,13C heteronuclear multiple bond correlation (HMBC), 
rotating Overhauser effect spectroscopy (ROESY) and double-quantum-filtered correlation 
spectroscopy (DQF-COSY) experiments were run at 400.1MHz using standard pulse programs 
from the Bruker library. Electrospray ionization mass spectrometry (ESIMS) spectra were recorded 
in negative or positive ion mode with a Waters ZQ quadrupole mass spectrometer on samples 
dissolved in methanol. High resolution electrospray ionization (HRESI) mass spectra were obtained 
with a Finnegan MAT 90 instrument. Analytical and preparative thin layer chromatography (TLC) 
analyses were performed on F254 0.25 and 0.5mm silica gel plates. Silver nitrate-impregnated silica 
gel plates were prepared as described.166 Sephacryl S 200 HR from Amersham Bioscience was used 
for tyrosinase purification. HPLC was carried out on an Agilent mod. 1100 apparatus equipped with 
a UV detector set at 280nm using octadecylsilane coated columns, 250 × 4.6 mm, or 22 x 250, 5 µm 
particle size, (Sphereclone, Phenomenex) for analytical or preparative runs, respectively at a flow 
rate of 1.0 mL/min or 15 mL/min. 
TLC eluants: 
40:60 cyclohexane-ethyl acetate (eluant A) 
60:40 cyclohexane-ethyl acetate (eluant B) 
95:5 ethyl acetate-cyclohexane containing 0.5% acetic acid (eluant C) 
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50:50 benzene-ethyl acetate containing 0.01% acetic acid (eluant D) 
98:2 chloroform-methyl alcohol (eluant E) 
HPLC eluants: 
70:30 H2O-acetonitrile (eluant I) 
60:40 H2O-acetonitrile (eluant II) 
90:10 H2O-acetonitrile (solvent A), acetonitrile (solvent B), 0-5 min 30% B, 5-30 min 30-55% B, 
30-40 min 55% B (eluant III). 
67:30:3 H2O-acetonitrile-acetic acid (eluant IV) 
50:50  1% acetic acid-acetonitrile (eluant V) 
 
 
PEROXIDASE CATALIZED REACTION  
 
 
Oxidation of 17βE by the Peroxidase/H2O2 System: General Procedure. To a solution of 17βE 
(5 mg, 1.9 x 10-5 mol) in methanol (5 mL) were added 0.1 M phosphate buffer, pH 7.4 (60 mL), and 
peroxidase (1 U/mL) sequentially. The mixture was then treated with hydrogen peroxide in aliquots 
(8 x 2.5 x 10-6 mol) every 10 min while being kept under stirring at room temperature. At different 
time intervals the reaction was carefully acidified at pH 5.0 and extracted three times with ethyl 
acetate (3 x 60 mL). The combined organic layers were dried over sodium sulfate and analyzed by 
HPLC (eluant III) and TLC (eluant A). In other experiments the reaction was carried out as above 
with the substrate at 3 x 10-7 M concentration using peroxidase (0.02 U/mg) and hydrogen peroxide 
(1 mol equiv) 
 
Oxidation of 1 by MnO2. A solution of 17βE (10 mg, 3.7 x 10-5 mol) in chloroform (10 mL) was 
treated with MnO2 (64 mg, 8 x 10-4 mol) and kept overnight at room temperature. The solid was 
removed by centrifugation, and the mixture was taken to dryness, taken up in methanol, and 
analyzed by HPLC (eluant III) and TLC (eluant A). 
 
Isolation of Compounds 1-8. For preparative purposes, reaction of 17βE with peroxidase/H2O2 
was run as described above using 500 mg (1.84 x 10-3 mol) of the starting material at 3.0 x10-4 M 
concentration. After workup of the reaction mixture, the residue obtained (480 mg) was fractionated 
by PLC (eluantA) to give seven fractions. Fraction A (15 mg, Rf = 0.68 eluant A) was further 
purified by preparative HPLC (eluant II) to give pure 2a (5 mg, tr = 8 min, eluant II, 1% yield) and 
2b (5 mg, tr = 17 min, eluant II, 1% yield). Fraction B (25 mg, Rf = 0.55 eluant A) was fractionated 
by PLC (eluant I) to give pure 4 (8 mg, tr = 27 min, eluant II, 1.6% yield) and 5 (8 mg, tr = 29 min, 
eluant II, 1.6% yield). Fraction C (15 mg, Rf = 0.45 eluant A) was purified by HPTLC (eluant E) to 
afford 3a (5 mg, tr = 9 min, eluant II, 1% yield) and 3b (5 mg, tr = 10 min, eluant II, 1% yield). 
Fraction D (20 mg, Rf = 0.43, eluant A) consisted of pure 1 (tr = 14 min, eluant II, 4% yield). 
Fraction E (22 mg, Rf = 0.33, eluant A) was purified by preparative HPLC (eluant II) to afford 6a (3 
mg, tr = 31 min, eluant II, 0.6% yield) and 6b (3 mg, tr = 32 min, eluant II, 0.6% yield). Fraction F 
(14 mg, Rf = 0.22, eluant A) was fractionated by preparative HPLC (eluant II) to give four bands 
corresponding to pure 7a (3 mg, tr = 24 min, eluant II,, 0.6% yield), 7b (3 mg, tr = 80 min, eluant II, 
0.6% yield), 8a (3 mg, tr = 34 min, eluant II, 0.6% yield), and 8b (3 mg, tr = 37 min, eluant II, 0.6% 
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yield). Fraction G (35 mg, Rf = 0.10 eluant A) was found to consist of a complex pattern of species 
and was not further purified. 
 
2,2’-Bis[estra-1,3,5(10)-trien-3,17β-diol] (1). UV [λmax (CH3OH)]: 288 nm. 1H NMR (CD3OD), δ 
(ppm): 0.75 (s, 3H x 2), 1.0-1.8 (m, 8H x 2), 1.9-2.1 (m, 4H x 2), 2.15 (m, 1H x 2), 2.25 (m, 1H x 
2), 2.85 (m, 1H x 2), 3.64 (m, 1H x 2), 6.31 (s, 1H x 2), 7.14 (s, 1H x 2). 13C NMR (CD3OD), δ 
(ppm): 12.6 (2 x CH3), 24.1 (2 x CH2), 29.3 (2 x CH2), 31.5 (2 x CH2), 31.8 (4 x CH2), 38.8 (2 x 
CH2), 41.1 (2 x CH), 45.1 (2 x C), 46.1 (2 x CH), 52.1 (2 x CH), 83.3 (2 x CH), 118.1 (2 x CH), 
127.0 (2 x C), 130.3 (2 x CH), 134.7 (2 x C), 139.1 (2 x C), 153.0 (2 x C). EI/MS (m/z): 542, [M]+. 
HREIMS (m/z): calcd mass for C36H46O4, 542.3396; found, 542.3401. 
4,4’-Bis[estra-1,3,5(10)-trien-3,17β-diol] (2a). UV [λmax (CH3OH)]: 288 nm. 1H NMR (CDCl3), δ 
(ppm): 0.80 (s, 3H x 2), 1.1-1.7 (m, 8H x 2), 1.78 (m, 1H x 2), 1.95 (m, 1H x 2), 2.11 (m, 1H x 2), 
2.15-2.30 (m, 2H x 2), 2.30-2.40 (m, 2H x 2), 3.73 (t, J ) 8.2 Hz, 1H x 2), 6. 87 (d, J ) 8.8 Hz, 1H x 
2), 
7.30 (d, J ) 8.8 Hz, 1H x 2). 13C NMR (CDCl3), δ (ppm): 11.9 (2 x CH3), 23.9 (2 x CH2), 27.1 (2 x 
CH2), 27.8 (2 x CH2), 28.1 (2 x CH2), 31.4 (2 x CH2), 37.5 (2 x CH2), 39.1 (2 x CH), 44.0 (2 x C), 
45.0 (2 x CH), 50.9 (2 x CH), 82.6 (2 x CH), 113.6 (2 x CH), 119.9 (2 x C), 128.0 (2 x CH), 134.4 
(2 x C), 137.8 (2 x C), 152.0 (2 x C). EI/MS (m/z): 542, [M]+. HREIMS (m/z): calcd mass for 
C36H46O4, 542.3396; found, 542.3393. 
2b. UV [λmax (CH3OH)]: 288 nm. 1H NMR (CDCl3), δ (ppm): 0.81 (s, 3H x 2), 1.1-1.7 (m, 8H x 2), 
1.79 (m, 1H x 2), 1.99 (s, 1H x 2), 2.12 (m, 1H x 2), 2.15-2.30 (m, 2H x 2), 2.30- 2.40 (m, 2H x 2), 
3.74 (t, J = 8.2 Hz, 1H x 2), 6. 86 (d, J = 8.8 Hz, 1H x 2), 7.32 (d, J = 8.8 Hz, 1H x 2). EI/MS (m/z): 
542, [M]+. HREIMS (m/z): calcd mass for C36H46O4, 542.3396; found, 542.3397. 
 
2,4’-Bis[estra-1,3,5(10)-trien-3,17β-diol] (3a). UV [λmax (CH3OH)]: 288 nm. 1H NMR (CDCl3), δ 
(ppm): 0.79 (s, 6H), 1.1-1.8 (m, 16H), 1.9-2.0 (m, 4H), 2.10 (m, 2H), 2.25 (m, 2H), 2.32 (m, 2H), 
2.50 (m, 2H), 2.85 (m, 2H), 3.73 (m, 2H), 6.77 (s, 1H), 6.85 (d, J = 8.4 Hz, 1H), 7.00 (s, 1H), 7.29 
(d, J = 8.4 Hz,1H). 13C NMR (CDCl3), δ (ppm): 11.9 (CH3), 23.9 (CH2), 27.3 (CH2), 27.8 (CH2), 
28.0 (CH2), 28.3 (CH2), 30.4 (CH2), 31.4 (CH2), 31.7 (CH2), 37.50 (CH2), 37.52 (CH2), 39.0 (CH), 
39.5 (CH), 44.0 (C), 44.8 (CH), 45.0 (CH), 50.8 (CH), 83.3 (CH), 113.6 (CH), 116.7 (CH), 117.4 
(C), 120.5 (C), 127.9 (CH), 128.3 (CH), 133.3 (C), 134.5 (C), 136.9 (C), 140.1 (C), 152.3 (C). 
EI/MS (m/z): 542, [M]+. HREIMS (m/z): calcd mass for C36H46O4, 542.3396; found, 542.3403. 
3b. UV [λmax (CH3OH)]: 288 nm. 1H NMR (CDCl3), δ (ppm): 0.78 (s, 6H), 1.1-1.8 (m, 16H), 1.9-
2.1 (m, 4H), 2.1- 2.3 (m, 4H), 2.3-2.5 (m, 4H), 2.92 (m, 2H), 3.72 (m, 2H), 6.78 (s, 1H), 6.87 (d, J = 
8.4 Hz, 1H), 6.99 (s, 1H), 7.29 (d, J = 8.4 Hz, 1H). EI/MS (m/z): 542, [M]+. HREIMS: calcd mass 
for 
C36H46O4, 542.3396; found, 542.3401. 
 
2-[[(17β)-17-Hydroxy-19-norpregna-1,3,5(10)-trien-3-yl]-oxy]estra-1,3,5(10)-trien-3,17β-diol 
(4). UV [λmax (CH3OH)]: 288 nm. 1H NMR (CDCl3), δ (ppm): 0.77 (s, 6H), 1.1-1.6 (m, 16H), 1.6-
1.8 (m, 2H), 1.90 (m, 2H), 1.95 (m, 1H), 2.0-2.2 (m, 5H), 2.32 (m, 1H), 2.83 (m, 3H), 3.71 (m, 2H), 
6.70 (d, J = 2.4 Hz, 1H), 6.74 (s, 1H), 6.76 (dd, J = 8.4, 2.4 Hz, 1H), 6.87 (s,1H), 7.22 (d, J = 8.4 
Hz, 1H). 13C NMR (CDCl3), δ (ppm): 11.8 (CH3), 23.9 (CH2), 27.0 (CH2), 27.1 (CH2), 27.9 (CH2), 
28.0 (CH2), 29.9 (CH2), 30.4 (CH2), 31.4 (CH2), 37.4 (CH2), 37.5 (CH2), 39.40 (CH), 39.45 (CH), 
44.0 (C), 44.8 (CH), 50.8 (CH), 82.6 (CH), 114.8 (CH), 116.7 (CH), 117.6 (CH), 117.7 (CH), 127.4 
(CH), 133.7 (C), 134.2 (C) 135.8 (C), 139.3 (C), 141.5 (C), 146.2 (C), 156.0 (C). EI/MS (m/z): 542, 
[M]+. HREIMS (m/z): calcd mass for C36H46O4, 542.3396; found, 542.3399. 
 
4-[[(17β)-17-Hydroxy-19-norpregna-1,3,5(10)-trien-3-yl]-oxy]estra-1,3,5(10)-trien-3,17β-diol 
(5). UV [λmax (CH3OH)]: 288 nm. 1H NMR (CDCl3), δ (ppm): 0.78 (s, 6H), 1.1-1.8 (m, 16H), 1.8-
1.9 (m, 2H), 1.9-2.0 (m, 2H), 2.0-2.2 (m, 4H), 2.33 (m, 2H), 2.40 (m, 1H), 2.73 (m, 1H), 2.81 (m, 
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2H), 3.73 (m, 2H), 6.60 (d, J = 2.4 Hz, 1H), 6.62 (dd, J = 8.4, 2.4 Hz, 1H), 6.86 (d, J = 8.4, 1H), 
7.10 (d, J = 8.4 Hz, 1H), 7.17 (d, J = 8.4 Hz, 1H). 13C NMR (CDCl3), δ (ppm): 11.8 (CH3), 23.9 
(CH2), 24.6 (CH2), 27.0 (CH2), 28.0 (CH2), 28.2 (CH2), 30.5 (CH2), 31.4 (CH2), 37.4 (CH2), 39.0 
(CH), 39.5 (CH), 44.0 (C), 44.8 (CH), 50.8 (CH), 82.7 (CH), 112.8 (CH), 113.8 (CH), 115.6 (CH), 
123.6 (CH), 127.5 (CH), 131.5 (C), 134.4 (C), 135.5 (C), 139.4 (C), 139.7 (C), 147.4 (C), 155.7 
(C). EI/MS (m/z): 542, [M]+. HREIMS (m/z): calcd mass for C36H46O4, 542.3396; found, 542.3402. 
 
2-[[(17β)-17-Hydroxy-19-norpregna-1,3,5(10)-trien-3-yl]-oxy]-4,2’bis[estra-1,3,5(10)-trien-
3,17β-diol] (6a). UV [λmax (CH3OH)]: 288 nm. 1H NMR (CDCl3), δ (ppm): 0.78 (s, 3H), 0.79 (s, 
3H) 0.80 (s, 3H), 1.1-1.7 (m, 21H), 1.70-1.85 (m, 3H), 1.85-2.00 (m, 5H), 2.1-2.2 (m, 5H), 2.2-2.3 
(m, 3H), 2.35 (m,2H), 2.45 (m, 1H), 2.55 (m, 1H), 2.85 (m, 4H), 3.74 (m, 3H), 6.75 (s, 1H), 6.76 (d, 
J = 2.4 Hz, 1H), 6.80 (dd, J = 8.4, 2.4 Hz, 1H), 6.98 (s, 1H), 7.04 (s, 1H), 7.23 (d, J = 8.4, 1H). 13C 
NMR (CDCl3), δ (ppm): 11.9 (CH3), 23.9 (CH2), 27.1 (CH2), 27.3 (CH2), 27.9 (CH2), 30.5 (CH2), 
31.4 (CH2), 31.7 (CH2), 37.5 (CH), 38.9 (C), 39.5 (C), 44.0 (CH), 44.8 (CH), 45.1 (CH), 50.9 (CH), 
82.7 (CH), 115.4 (CH), 116.4 (CH), 117.8 (CH), 118.4 (CH), 119.8 (C), 124.3 (C), 127.4 (CH), 
128.3 (CH), 132.3 (C), 133.6 (C), 133.9 (C), 134.3 (C), 136.0 (C), 139.3 (C), 142.2 (C), 144.6 (C), 
151.6 (C), 155.9 (C). EI/MS (m/z): 812, [M]+. HREIMS (m/z): calcd mass for C54H68O6, 812.5016; 
found, 812.5035. 
 
6b. UV [λmax (CH3OH)]: 288 nm. 1H NMR (CDCl3), δ (ppm): 0.77 (s, 3H), 0.78 (s, 3H) 0.79 (s, 
3H), 1.1-1.7 (m, 24 H), 1.7-2.0 (m, 5H), 2.0-2.3 (m, 8H), 2.40 (m, 2H), 2.50 (m, 2H), 2.87 (m, 4H), 
3.72 (m, 3H), 6.75 (d, J = 2.4 Hz, 1H), 6.77 (s, 1H), 6.81 (dd, J = 8.4, 2.4 Hz, 1H), 6.98 (s, 1H), 
7.03 (s, 1H), 7.24 (d, J = 8.4, 1H). EI/MS (m/z): 812, [M]+. HREIMS (m/z): calcd mass for 
C54H68O6, 812.5016; found, 812.5026. 
 
2,2’4’2”-Tris[estra-1,3,5(10)-trien-3,17β-diol] (7a). UV [λmax (CH3OH)]: 288 nm. 1H NMR 
(CDCl3), δ (ppm): 0.78 (s, 3H), 0.80 (s, 6H), 1.1-1.9 (m, 24H), 1.9-2.0 (m, 6H), 2.1-2.4 (m, 10H), 
2.42 (m, 2H), 2.90 (m, 3H), 3.73 (m, 3H), 6.76 (s, 1H), 6.79 (s, 1H), 7.04 (s, 1H), 7.20 (s, 1H), 7.32 
(s, 1H). EI/MS (m/z): 812, [M]+. HREIMS (m/z): calcd mass for C54H68O6, 812.5016; found, 
812.5005. 
 
7b. UV [λmax (CH3OH)]: 288 nm. 1H NMR (CDCl3), δ (ppm): 0.77 (s, 3H), 0.78 (s, 6H), 1.1-1.9 (m, 
24H), 1.9-2.0 (m, 5H), 2.0-2.2 (m, 5H), 2.2-2.5 (m, 8H), 2.90 (m, 3H), 3.73 (m, 3H), 6.76 (s, 1H), 
6.78 (s, 1H), 7.04 (s, 1H), 7.21 (s, 1H), 7.32 (s, 1H). 13C NMR (CDCl3), δ (ppm): 11.8 (CH3), 23.9 
(CH2), 24.0 (CH2), 24.5 (CH2), 27.2 (CH2), 27.9 (CH2), 29.3 (CH2), 30.1 (CH2), 30.4 (CH2), 30.5 
(CH2), 31.4 (CH2), 37.5 (CH2), 39.1 (CH), 39.4 (CH), 39.6 (CH), 44.0 (C), 44.8 (CH), 45.1 (CH), 
50.9 (CH), 82.7 (CH), 116.9 (CH), 118.2 (CH), 121.9 (C), 122.5 (C), 123.0 (C), 128.6 (CH), 128.9 
(CH), 130.0 (CH), 133.3 (C), 133.9 (C), 137.4 (C), 138.3 (C), 140.0 (C), 150.9 (C), 151.1 (C). 
EI/MS 
(m/z): [M]+. HREIMS (m/z): calcd mass for C54H68O6, 812.5016; found, 812.5027. 
 
2,2’4’4”-Tris[estra-1,3,5(10)-trien-3,17β‚-diol] (8a). UV [λmax (CH3OH)]: 288 nm. 1H NMR 
(CDCl3), δ (ppm): 0.79 (s, 3H), 0.80 (s, 3H), 0.81 (s, 3H), 1.2-1.8 (m, 24H), 1.8-2.0 (m, 6H), 2.0-
2.2 (m, 4H), 2.2-2.4 (m, 8H), 2.89 (m, 3H), 3.74 (m, 3H), 6.76 (s, 1H), 6.88 (d, J = 8.4 Hz, 1H), 
7.22 (s, 1H), 7.32 (d, J = 8.4, 1H), 7.34 (s, 1H). EI/MS (m/z): [M]+. HREIMS (m/z): calcd mass for 
C54H68O6, 812.5016; found, 812.5003. 
 
8b. UV [λmax (CH3OH)]: 288 nm. 1H NMR (CDCl3), δ (ppm): 0.79 (s, 3H), 0.80 (s, 6H), 1.1-1.8 (m, 
24H), 1.8-2.0 (m, 5H), 2.1-2.2 (m, 5H), 2.2-2.5 (m, 8H), 2.8-2.9 (m, 3H), 3.73 (m, 3H), 6.76 (s, 
1H), 6.89 (d, J = 8.4 Hz, 1H), 7.22 (s, 1H), 7.33 (d, J = 8.4, 1H), 7.36 (s, 1H). 13C NMR (CDCl3), δ 
(ppm): 11.8 (CH3), 11.9 (CH3), 23.8 (CH2), 24.0 (CH2), 24.5 (CH2), 26.5 (CH2), 28.1 (CH2), 29.7 
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(CH2), 30.5 (CH2), 31.1 (CH2), 31.4 (CH2), 37.5 (CH2), 38.6 (CH), 39.5 (CH), 42.1 (C), 44.0 (CH), 
44.9 (CH), 48.8 (CH), 50.8 (CH), 82.7 (CH), 118.3 (CH), 118.6 (CH), 118.9 (C), 122.6 (C), 122.7 
(C), 128.2 (CH), 130.1 (CH), 130.2 (CH), 132.6 (C), 134.3 (C), 136.3 (C), 136.5 (C), 138.2 (C), 
148.0 (C), 151.5 (C), 152.1 (C). EI/MS (m/z): 812, [M]+. HREIMS (m/z): calcd mass for C54H68O6, 
812.5016; found, 812.5024. 
 
 
TYROSINASE CATALIZED REACTIONS  
 
 
Oxidation of 17βE by the Tyrosinase/O2 system: General Procedure. To a solution of 17βE (5 
mg, 1.9 x 10-5 mol) predissolved in methanol (1 mL), 0.1 M phosphate buffer (600 mL) (pH 7.4) 
was added followed by tyrosinase in two aliquots at 3 h intervals up to a 10 U/mL final 
concentration. After 18 h, the reaction mixture was treated with NaBH4 (1 mg), carefully acidified 
to pH 5.0, and extracted with ethyl acetate (3 x 150 mL). The combined organic layers were dried 
over sodium sulfate and analyzed by HPLC (eluant IV). In other experiments, the reaction was 
carried out as above with the substrate at concentrations varying in the range of 1 nM to 30 µM and 
tyrosinase at 1 U/mL final concentration when the substrate was 1 nM to 1 µM. When required, 
tropolone (1 nM) was added to the incubation mixture with the substrate at 1 µM concentration. 
Oxidation of 2OHE and 4OHE by Tyrosinase. To a solution of 2OHE or 4OHE (5 mg, 1.7 x 10-5 
mol) in methanol (1 mL), 0.1 M phosphate buffer (300 mL) (pH 7.4) was added followed by 
tyrosinase in two aliquots at 3 h intervals up to a 5 U/mL final concentration. The resulting pale 
yellow solution was taken under stirring for 18 h and then treated with NaBH4, carefully acidified to 
pH 5.0, and extracted three times with ethyl acetate (3 x 60 mL). The combined organic layers were 
dried over sodium sulfate and analyzed by HPLC (eluant IV). In other experiments, the reaction 
was carried out as above with the substrate at concentrations varying in the range of 1-60 µM. 
Isolation of Compounds 9-15. For preparative purposes, the oxidation of 2OHE with tyrosinase 
was run as described above using 100 mg (3.5 x 10-4 mol) of the starting material at 60 µM 
concentration. After work up of the reaction mixture as above, the residue obtained (90 mg) was 
fractionated by HPLC (eluant IV) to give five fractions extracted with AcOEt. Fraction A (8 mg, tR 
7 min) consisted of pure 9 (8% yield), while fraction B (2 mg, tR 26 min) contained compound 10 
(2% yield). Fraction C (7 mg, tR 31 min) was found to be a mixture of compounds 11 and 12 based 
on NMR analysis and was further purified by fractionation on silver nitrate-impregnated TLC plates 
(eluant C) to afford compounds 12 (Rf 0.45, 3 mg, 3% yield) and 11 (Rf 0.50, 2 mg, 2% yield). 
Fractions D (5 mg, tR 56 min) and E (5 mg, tR 82 min) contained compounds 13 (5% yield) and 14 
(5% yield). The reaction of 4OHE was run under the same conditions using 100 mg of the starting 
material at 60 µM concentration. After work up as above, preparative HPLC fractionation (eluant 
IV) followed by AcOEt extraction of the eluates afforded one main fraction (6 mg, tR 35 min) 
consisting of compound 15 (6% yield). 
 
2-Hydroxy-6-oxo-estra-1,3,5(10)-trien-3,17β-diol (9). UV λmax (CH3OH): 235, 280 and 321 nm. 
ESI(-)/MS: m/z 301 [M- H]. ESI(-)HRMS calculated mass for C18H21O4 [M - H], 301.1440; found, 
m/z 301.1432. 1H NMR and 13C NMR (CD3OD) spectra were consistent with those reported (28). 
 
2-Hydroxy-estra-1,3,5,6,8-pentaene-3,17β-diol (10). UV λmax (CH3OH): 241 and 288 nm. 1H 
NMR (CD3OD) δ (ppm): 0.65 (s, 3H), 3.01-3.11 (m, 2H), 3.89 (m, 1H), 6.93 (d, J = 8.4 Hz, 1H, H-
7), 7.04 (s, 1H, H-4), 7.22 (s, 1H, H-1), 7.36 (d, J = 8.4 Hz, 1H, H-6). 13C NMR (CD3OD) ä (ppm): 
11.5 (CH3), 24.3 (CH2), 26.3 (CH2), 36.5 (CH2), 44.3 (C), 48.1 (CH), 81.0 (CH), 113.3 (CH), 118.5 
(CH), 127.4 (CH), 130.0 (C), 131.2 (C), 132.3 (C), 137.2 (C), 148.3 (C), 149.0 (C). ESI(-)/MS: m/z 
283 [M - 
H]. ESI(-)HRMS calculated mass for C18H19O3 [M - H], 283.1334; found, m/z 283.1379. 
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2-Hydroxy-estra-1,3,5(10),9-tetraen-3,17β-diol (11). UV λmax (CH3OH): 230, 270, 290, 316 nm. 
1H NMR (CD3OD) δ (ppm): 0.77 (s, 3H), 2.55-2.75 (m, 2H), 3.75 (t, J = 8.8 Hz, 1H), 5.98 (m, 1H, 
H-11), 6.44 (s, 1H, H-4), 6.99 (s, 1H, H-1). 13C NMR (CD3OD) δ (ppm): 12.0 (CH3), 25.4 (CH2), 
30.4 (CH2), 30.7 (CH2) 31.1 (CH2), 40.8 (CH2), 43.2 (C), 51.2 (CH), 83.1 (CH), 111.8 (CH), 116.7 
(CH), 118.0 (CH), 128.5 (C), 129.8 (C), 137.5 (C), 145.1 (C), 146.2 (C). ESI(-)/MS: m/z 285 [M - 
H]. ESI(-)HRMS calculated mass for C18H21O3 [M - H], 285.1491; found, m/z 285.1517. 
 
2-Hydroxy-estra-1,3,5,6-tetraen-3,17β-diol (12). UV λmax (CH3OH): 222, 283, 316 nm. 1H NMR 
(CD3OD) δ (ppm): 0.76 (s, 3H), 3.67 (t, J = 8.4 Hz, 1H, H-17), 5.75 (dd, J = 9.6, 2.0 Hz, 1H, H-7), 
6.29 (dd, J = 9.6, 2.8 Hz, 1H, H-6), 6.50 (s, 1H, H-4), 6.71 (s, 1H, H-1). 13C NMR (CD3OD) δ 
(ppm): 11.9 (CH3), 24.4 (CH2), 26.0 (CH2), 31.3 (CH2), 40.9 (CH), 44.1 (CH), 45.3 (C), 52.0 (CH), 
82.8 (CH), 112.9 (CH), 115.1 (CH), 128.5 (C), 129.2 (CH), 130.3 (CH), 133.2 (C), 144.4 (C), 145.7 
(C). ESI(-)MS: m/z 285 [M - H]. ESI(-)HRMS calculated mass for C18H21O3 [M - H], 285.1491; 
found, m/z 285.1479. 
 
2-Hydroxy-1-[[(17β)-2,17-dihydroxy-19-norpregna-1,3,5(10)-trien-3-yl]oxy]estra-
1,3,5(10)trien-3,17β-diol. (13). UV λmax (CH3OH): 290 nm. 1H NMR (CD3OD) δ (ppm): 0.64 (s, 
3H), 0.69 (s, 3H), 2.55 (m, 1H), 2.80 (m, 1H), 3.57 (m, 1H), 3.67 (m, 1H), 6.08 (s, 1H, H-4), 6.29 
(s, 1H, H-4), 6.80 (s, 1H, H-1). 13C NMR (CD3OD) δ (ppm): 12.2 (CH3), 12.3 (CH3), 27.1 (CH2), 
28.7 (CH2), 20.3 (CH2), 31.5 (CH2), 38. 3 (CH2), 38.6 (CH2), 38.9 (CH2), 39.0 (CH2), 41.8 (CH), 
44.5 (C), 44.9 (C), 46. 2 (CH), 47.4(CH), 51.1 (CH), 51.2 (CH), 83.0 (CH), 118.2 (CH), 123.4 (C), 
127.1 (C), 132.3 (C), 135.5 (C), 142.6 (C), 145.2 (C), 145.1 (C). ESI(-)/MS: m/z 573 [M - H]. ESI(-
)HRMS calculated mass for C36H45O6 [M - H], 573.3216; found, m/z 573.3203. 
 
2-Hydroxy-1-[[(17β)-2,17-dihydroxy-19-norpregna-1,3,5(10)-trien-3-yl]oxy]estra-1,3,5,6,8 
pentaen-3,17β-diol. (14). UV λmax (CH3OH): 238 and 289 nm. 1H NMR (CD3OD) δ (ppm): 0.65 
(s, 3H), 0.77 (s, 3H), 3.08-3.11 (m, 2H), 3.66 (m, 1H), 3.70 (m, 1H), 6.14 (s, 1H, H-4), 6.62 (d, J 
= 8.8 Hz, 1H, H-7), 6.81 (s, 1H, H-4), 7.17 (d, J = 8.8 Hz, 1H, H-6), 7.19 (s, 1H, H-1). 13C NMR 
(CD3OD) δ (ppm): 10.5 (CH3) 11.0 (CH3), 24.1 (CH2), 28.3 (CH2), 30.4 (CH2), 31.0 (CH2), 32.4 
(CH2), 36.3 
(CH2), 38.3 (CH2), 44.2 (C), 45.1 (C), 48.4 (CH), 52.7 (CH), 105.0 (CH), 113.1 (CH), 116.2 (CH), 
122.5 (CH), 125.7 (CH), 127.2 (C), 130.2 (C), 131.1 (C), 132.2 (C), 134.2 (C), 135.3 (C), 144.3 
(C), 
145.0 (C), 146.2 (C), 147.5 (C). ESI/MS: m/z 569 [M - H]. ESI(-)HRMS calculated mass for 
C36H41O6 [M - H], 569.2903; found, m/z 569.2935. 
4-Hydroxy-9,11-dehydroestra-1,3,5(10)-trien-3,17β-diol (15). UV λmax (CH3OH): 225 and 273 
nm. 1H NMR (CD3OD) δ (ppm): 0.78 (s, 3H), 1.1-1.5 (m, 5H), 1.94-2.10 (m, 2H), 2.19 (m, 1H), 
2.50 (m, 2H), 2.97 (m, 2H), 3.74 (t, J = 8.5 Hz, 1H), 6.05 (m, 1H, H-10), 6.58 (d, J = 9.0 Hz, 1H, 
H-2), 6.97 (d, J = 9.0 Hz, 1H, H-1). 13C NMR (CD3OD) δ (ppm): 12.0 (CH3), 24.9 (CH2), 25.4 
(CH2), 31.2 (CH2), 31.3 (CH2), 40.4 (CH), 40.8 (CH2), 43.2 (C), 50.0 (CH), 83.1 (CH), 114.4 (CH), 
116.8 (CH), 118.1 (CH), 125.7 (C), 129.0 (C), 137.8 (C), 144.2(C), 146.4 (C). ESI/MS: m/z 285 [M 
- H]. HREIMS calculated mass for C18H22O3 [M - H], 285.1491; found, m/z 285.1525. 
 
CATECHOL ESTROGENS PREPARATION    
 
 
Preparation of the Catechol Estrogens: General Procedure. Solid IBX (2.5 equiv) was added to 
a solution of 17βE or 2 (200 mg) in CHCl3/MeOH 3: 2 v/v (40 mL) at _25 °C. A yellow-to-orange 
color developed and the mixture was stirred for 24 h. Methanolic NaBH4 (15mg in 1 mL) was then 
added at _25 °C under vigorous stirring until the color disappeared (usually within 5min). After 
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mild acidification with acetic acid (200–500 µL) to remove excess NaBH4, the mixture was washed 
five times with equal volumes of a saturated NaCl solution containing 10% sodium dithionite 
buffered at pH 7.4 with sodium phosphate. Evaporation of the organic layer eventually furnished 
the desired products 3/4 or 5/6, which could be separated by preparative TLC (eluant D) on silica. 
 
2-Hydroxy-estra-1,3,5(10)-trien-3,17β-diol (2OHE). Pale yellow powder. UV (MeOH): λmax 281 
nm. ESI/MS m/z: 287 [M-H+]; ESI-HRMS calculated for C18H23O3 (M-H+) 287.1647, found 
287.1649. 1H NMR (CDCl3), δ (ppm) selected signals: 0.78 (s, 3H, CH3), 3.73 (t, J = 8.8 Hz, 1H, 
CHOH), 6.58 (s, 1H), 6.81 (s, 1H).  
 
4-Hydroxy-estra-1,3,5(10)-trien-3,17β-diol (4OHE). Pale yellow powder. UV (MeOH): λmax 280 
nm. ESI/MS m/z: 287 [M-H+]; ESI-HRMS calculated for C18H23O3 (M-H+) 287.1647, found 
287.1648. 1H NMR (CDCl3), δ (ppm) selected signals: 0.77 (s, 3H, CH3), 3.73 (t, J = 8.8 Hz, 1H, 
CHOH), 6.69 (d, J = 8.4 Hz, 1H), 6.76 (d, J = 8.4 Hz, 1H). 
 
2-Hydroxyestrone (17). Pale yellow powder. UV (MeOH): λmax 282 nm. ESI/MS m/z: 285[M-H+]; 
ESI-HRMS calculated for C18H21O3 (M-H+) 285.1491, found 285.1491. 1H NMR (CDCl3), δ (ppm) 
selected signals: 0.78 (s, 3H, CH3), 6.61 (s, 1H,), 6.82 (s, 1H). 
 
4-Hydroxyestrone (18). Pale yellow powder. UV (MeOH): λmax 282 nm. ESI/MS m/z: 285[M-H+]; 
ESI-HRMS calculated for C18H21O3 (M-H+) 285.1491, found 285.1490, found 288.1725. 1H NMR 
(CDCl3), δ (ppm) selected signals: 0.77 (s, 3H, CH3), 6.67 (d, J = 8.4 Hz, 1H), 6.74 (d, J = 8.4 Hz, 
1H). 
 
Catechol. Brownish powder. UV (MeOH): λmax 280 nm. ESI/MS m/z: 109 [M-H+]; ESI-HRMS 
calculated for C6H5O2 (M-H+) 109.0289, found 109.0291. 
 
4,5-Dimethylcatechol. Pale brown powder. UV (MeOH): λmax 280 nm. ESI/MS m/z: 137 [M-H+]; 
ESI-HRMS calculated for C8H9O2 (M-H+) 137.0603, found 137.0604. 1H NMR (CDCl3), δ (ppm) 
selected signals: 2.20 (s, 6H, CH3), 5.51 (s, 2H). 
 
3,4-Dimethylcatechol. Pale brown powder. UV (MeOH): λmax 280 nm. ESI/MS m/z: 137 [M-H+]; 
ESI-HRMS calculated for C8H9O2 (M-H+) 137.0603, found 137.0605. 1H NMR (CDCl3), δ (ppm) 
selected signals: 2.21 (s, 3H, CH3), 2.22 (s, 3H, CH3), 5.53 (d, J = 8.4 Hz, 1H), 6.64 (d, J = 8.4 Hz, 
1H). 
 
3,6-Dimethylcatechol. Pale brown powder. UV (MeOH): λmax 281 nm. ESI/MS m/z: 137 [M-H+]; 
ESI-HRMS calculated for C8H9O2 (M-H+) 137.0603, found 137.0604. 1H NMR (CDCl3), δ (ppm) 
selected signals: 2.22 (s, 6H, CH3), 6.61 (s, 2H). 
 
1,2-Dihydroxynaphthalene. Pale blue powder ESI/MS m/z: 159 [M-H+]; ESI-HRMS calculated 
for C10H7O2 (M-H+) 159.0446, found 159.0449. 
 
7,8-Dihydroxyquinoline. Pale red powder ESI/MS m/z: 160 [M-H+]; ESI-HRMS calculated for 
C9H6O2N (M-H+) 160.0398, found 160.0403. 1H NMR (CDCl3), d (ppm): 7.22 (d, J = 8.8 Hz, 1H), 
7.29 (dd, J = 8.4, 4.4, Hz, 1H), 7.31 (d, J = 8.8 Hz, 1H), 8.16 (dd, J = 8.4, J = 1.6, Hz, 1H), 7.29 (dd, 
J = 4.4, J = 1.6, Hz, 1H). 
 
3-tert-Butylcatechol. Pale brown powder. UV (MeOH): λmax 281 nm. ESI/MS m/z: 165[M-H+]; 
ESI-HRMS calculated for C10H13O2 (M-H+) 165.0915, found 165.0917. 1H NMR (CD3OD), δ 
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(ppm): 1.40 (s, 9H, CH3), 6.55 (dd, J = 8.0, J = 7.5, Hz, 1H), 6.64 (dd, J = 8.0, J = 1.5, Hz, 1H), 6.70 
(dd, J = 7.5, J = 1.5, Hz, 1H). 
 
 
10β-SUBSTITUTED 17β-HYDROXYESTRA-1,4-DIEN-3-ONES PREPARATION 
 
Preparation of 10β, 17β-dihydroxyestra-1,4-dien-3-one (1): General Procedure. A solution of 
17βE (100 mg, 0.37 mmol) in ethyl acetate (16 mL) was added under vigorous stirring to a solution 
of potassium permanganate (116 mg, 0.74 mmol) in 0.05M aqueous HCl (16 mL). After 30 s, when 
substrate consumption was complete (TLC evidence), the mixture was extracted with ethyl acetate 
(3×75 mL), the organic layers were collected, and taken to dryness to afford pure 26 (80 mg, 75% 
yield, Rf = 0.30) as crystals from ethyl acetate. 
 
26: m.p. 217–219 ◦C; UV (MeOH): λmax 243 nm; 1H and 13C NMR (see Table 1); ESI(−)MS m/z: 
287([M−H]−). Anal. calcd. for C18H24O3: C, 74.97; H, 8.39. Found: C, 75.00; H, 8.42. 
 
Preparation of 10β-Chloro-17β-hydroxyestra-1,4-dien-3-one (27): General Procedure. 17βE 
(100 mg, 0.37 mmol) in methanol (7 mL) was added under vigorous stirring to 0.01M aqueous HCl 
(20 mL) containing NaClO2 (66 mg, 0.74 mmol). After 30 min reaction time, when substrate 
consumption was complete (HPLC evidence, eluant V), the mixture was extracted with ethyl 
acetate (3×75 mL), the organic layers were collected, taken to dryness, and the residue fractionated 
on silica plates (eluant A) to afford pure 27 (50 mg, 44% yield, Rf = 0.49, RT = 12.7 min) as 
colourless crystals from ethyl acetate, 28 (2 mg, 2% yield, Rf = 0.17, RT = 5.5 min), 29 (7 mg, 6% 
yield, Rf = 0.55, RT = 19.3 min), 30 (12 mg, 9% yield, Rf = 0.52, RT = 21.2 min). 
27: m.p. 158–160 °C rif. 117; UV (CH3OH): λmax 241, 280 (sh) nm; 1H and 13C NMR (see Table 3); 
ESI(+)MS m/z: 307 ([M+H]+, 100), 309 ([M+2+H]+, 35). Anal. calcd. for C18H23O2Cl: C, 70.46; H, 
7.56. Found C, 70.89; H, 7.45. 
 
4-chloro-10β, 17β-dihydroxyestra-1,4-dien-3-one (28): UV (CH3OH): λmax 249, 289 nm; 1H 
NMR (CDCl3), δ (ppm) 0.85 (3H, s), 1.03 (1H, m), 1.07 (2H, m), 1.09 (1H, m), 1.34 (1H, m), 1.45 
(1H, m), 1.50 (1H, m), 1.64 (1H, m), 1.65 (1H, m), 1.86 (1H, m), 2.00 (2H, m), 2.09 (1H, m), 2.60 
(1H, m), 3.17 (1H, m), 3.64 (1H, m), 6.31 (1H, d, J = 10.4 Hz), 7.12 (1H, d, J = 10.4 Hz); 13C NMR 
(CDCl3), δ (ppm) 11.0 (CH3), 22.8 (CH2), 23.6 (CH2), 28.7 (CH2), 30.4 (CH2), 31.9 (CH2), 35.0 
(CH), 36.1 (CH2), 43.0 (C), 49.7 (CH), 55.3 (CH), 72.8 (C), 81.5 (CH), 126.9 (CH), 127.0 (C), 
150.6 (CH), 160.6 (C), 178.7 (C); ESI(−)MS m/z: 321 ([M−H]−, 100), 323 ([M+2−H]−, 35). 
 
2,10β-dichloro-17β-hydroxyestra-1,4-dien-3-one (29): UV (CH3OH): λmax 253, 288 (sh) nm; 1H 
NMR rif. 117; ESI(+)MS m/z: 341 ([M +H]+, 100), 343 ([M+2+H]+, 63), 345 ([M+4+H]+, 12). 
 
4,10β-dichloro-17β-hydroxyestra-1,4-dien-3-one (30): UV (CH3OH): λmax 247, 289 nm; 1H NMR 
rif. 117; ESI(+)MS m/z: 341 ([M +H]+, 100), 343 ([M+2+H]+, 63), 345 ([M+4+H]+, 15). 
 
 
 
HALOGENATION 
 
Iodination of estradiol: General Procedure. A solution of 17βE (50 mg, 0.2 mmol) in 10 ml 
MeOH was added to a well-stirred solution of NaClO2 (66 mg, 0.8 mmol) and NaI (220 mg, 1.6 
mmol) in H2O (10 ml). This mixture was treated with 0.5 mL HCl conc (6 mmol) and allowed to 
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stir at room temperature. The reaction was monitored by TLC. After completion of reaction (30 
min), the mixture was diluted with water (20 mL) and extracted with ethyl acetate (3x30 mL). The 
combined organic layers were washed with an aqueous solution of sodium tiosulphate, and sodium 
chloride to remove excess iodine, and dried over anhydrous sodium sulphate and concentrated 
under reduced pressure. The crude product was purified by PLC (eluant B) to give products 33 (Rf = 
0.75, 36 mg, 38 % yield) and 32 (Rf = 0.70, 25 mg, 35% yield).  
 
2,4-diiodo-17β-estradiol (33): ESI(-)MS m/z: 523 [M-H]−; 1H NMR (CDCl3), δ (ppm): 0.72 (s, 
3H), 3.68 (t, 1H), 7.57 (s, 1H). 
 
4-iodo-17β-estradiol (32): ESI(-)MS m/z: 397 [M-H]−; 1H NMR (CD3OD), δ (ppm): 0.78 (s, 3H), 
3.55 (t, 1H), 6.60 (d, J = 8.8 Hz, 1H),  7.08 (d, J = 8.8 Hz, 1H). 
 
2,4,6-triiodophenol: ESI(-)MS m/z: 471 [M-H]−; 1H NMR (CDCl3), δ (ppm): 7.95 (s, 2H). 
2,6-diiodo-4-nitrophenol: ESI(-)MS m/z: 389 [M-H]−; 1H NMR (acetone-d6), δ (ppm): 8.62 (s, 
2H). 
2,4,6-triiodoresorcine: ESI(-)MS m/z: 486 [M-H]−; 1H NMR (CDCl3), δ (ppm): 7.93 (s, 1H). 
2,4-diiodoaniline: ESI(+)MS m/z: 346 [M+H]+; 1H NMR (CD3OD), δ (ppm): 6.57 (d, J = 8.2 Hz, 
1H), 7.33 (dd, J = 8.2, 2.0 Hz, 1H), 7.80 (d, J = 2.0 Hz, 1H). 
2-iodo-4-nitroaniline: ESI(+)MS m/z: 265 [M+H]+, 287 [M+Na+]; 1H NMR (CDCl3), δ (ppm): 
6.70 (d, J = 8.7 Hz, 1H), 8.04 (dd, J = 8.7, 2.4 Hz, 1H), 8.54 (d, J = 2.4 Hz, 1H). 
1-iodo-2-naphtol: ESI(+)MS m/z: 269 [M+H]+; 1H NMR (acetone-d6), δ (ppm): 7.29 (d, J = 9.0, 
1H), 7.37 (t, J = 7.2 Hz, 1H), 7.56 (t, J = 7.5 Hz, 1H), 7.81 (d, J = 8.1 Hz, 1H), 7.82 (d, J = 9.0, 
1H), 8.06 (d, J = 8.1, 1H), 9.52 (s, 1H). 
8-hydroxy-5,7-diiodoquinoline: ESI(+)MS m/z: 398 [M+H]+; 1H NMR (CD3OD), δ (ppm): 7.53 
(dd, J = 8.4, 8.7 Hz, 1H), 8.25 (dd, J = 8.4, 1.5 Hz, 1H), 8.32 (s, 1H), 8.80 (dd, J = 8.7, 1.5 Hz, 1H). 
3-iodo-5-nitroindole: IR νmax 3460, 1755, 1622, 1525, 1472, 1341 cm-1; ESI(+)MS m/z: 311 
[M+Na]+; 1H NMR (CD3OD), δ  (ppm): 7.51 (d, J = 9.0 Hz, 1H), 7.56 (d, J = 2.2 Hz, 1H), 8.05 (dd, 
J = 9.0, 2.2 Hz, 1H), 8.24 (d, J = 2.1 Hz, 1H); 13C NMR (CD3OD), δ (ppm): 58.9 (C), 113.7 (CH), 
118.8 (CH), 119.2 (CH), 131.4 (C), 134.9 (CH), 141.4 (C), 143.9 (C). 
2,4,5-triiodoimidazole: ESI(-)MS m/z: 444 [M-H]−. 
Iodination of estradiol: General Procedure. A solution of NaClO2 (7 mg, 0.1 mmol) and NaI (14 
mg, 0.1 mmol) in 5 mL MeOH was added 17βE (50 mg, 0.2 mmol) under stirring. This mixture 
was treated with 0.05 mL HCl conc (0.6 mmol) and allowed to stir at room temperature. The 
reaction was monitored by TLC. After 10 min, the mixture was diluted with water (20 mL) and 
extracted with ethyl acetate (3x25 mL). The combined organic layers were dried over anhydrous 
sodium sulphate and concentrated under reduced pressure. The crude product was purified by PLC 
(eluant B) to give products 31 (Rf = 0.63, 30 mg, 40 % yield) and 17βE (Rf = 0.50, 10 mg).  
2,-iodo-17β-estradiol (31): ESI(-)MS m/z: 397 [M-H]−; 1H NMR (CD3OD), δ (ppm): 0.76 (s, 3H), 
3.63 (t, 1H), 6.53 (s, 1H), 7.49 (s, 1H). 
 
 66 
 
Bromination of estradiol: General Procedure. A solution of 17βE (50 mg, 0.2 mmol) in 10 ml 
MeOH was added to a well-stirred solution of NaClO2 (33 mg, 0.4 mmol) and NaBr (76 mg, 0.8 
mmol) in H2O (10 ml). This mixture was treated with 0.5 ml HCl conc (6 mmol) and allowed to stir 
at room temperature. The reaction was monitored by TLC. After completion of reaction (30 min), 
the mixture was diluted with water (20 mL) and extracted with ethyl acetate (3x30 mL). The 
combined organic layers were dried over anhydrous sodium sulphate and concentrated under 
reduced pressure. The crude product was purified by PLC (eluant B) to give products 36 (Rf = 0.80, 
5 mg, 6 % yield) and 35 (Rf = 0.61, 28 mg, 35 % yield).  
 
2,4-dibromo-17β-estradiol (35): ESI(-)MS m/z: 429 ([M-H]−, 100), 431 ([M+2-H+], 190), 433 
([M+4-H+], 93); 1H NMR (CD3OD), δ (ppm): 0.72 (s, 3H), 3.63 (t, 1H), 7.34 (s, 1H). 
 
2,4-dibromoestrone (36): ESI(-)MS m/z: 427 ([M-H]−, 100), 429 ([M+2-H]−, 192), 431 ([M+4-
H]−, 95); 1H NMR (CD3OD), δ (ppm): 0.90 (s, 3H), 7.41 (s, 1H). 
 
Bromination of estradiol: General Procedure. A solution of NaClO2 (7 mg, 0.1 mmol) and NaBr 
(9.5 mg, 0.1 mmol) in 5 mL MeOH was added 17βE (50 mg, 0.2 mmol) under stirring. This 
mixture was treated with 0.1 ml HCl conc (1 mmol) and allowed to stir at room temperature. The 
reaction was monitored by TLC. After 10 min, the mixture was diluted with water (20 mL) and 
extracted with ethyl acetate (3x25 mL). The combined organic layers were dried over anhydrous 
sodium sulphate and concentrated under reduced pressure. The crude product was purified by PLC 
to give products 34 (Rf = 0.65, 22 mg, 35 % yield) and 17βE (Rf = 0.55, 25 mg).  
 
2-bromo-17β-estradiol (34): ESI(-)MS m/z: 350 ([M-H]−, 100), 352 ([M+2-H]−, 98); 1H NMR 
(CD3OD), δ (ppm): 0.76 (s, 3H), 3.64 (t, 1H), 6.58 (s, 1H), 7.28 (s, 1H). 
 
 
Bromination of estradiol by NaBrO3/NaS2O4: General Procedure. To a solution of NaBrO3 (832 
mg, 6 mmol) in water (20 mL) was added 17βE (50 mg, 0.2 mmol) in ethyl acetate (25 mL), 
followed by a solution of NaS2O4 (96 mg, 6 mmol) in water (40 mL) over a period of about 15 min, 
and the mixture was stirred at room temperature for 30 min. The orange mixture was poured into 40 
mL of ethyl acetate. After separation of the phases, the aqueous layer was extracted twice with ethyl 
acetate, and the combined organic layer was dried over MgSO4. The solvents were then removed in 
vacuo, and the residue was purified by PLC (eluant A) to give compounds 37 (Rf = 0.59, 15 mg, 15 
% yield) and 38 (Rf = 0.82, 5 mg, 6% yield). 
 
3-hydroxy-2,4,10-tribromo-9,10-secoestra-1(10),2,4-trien-9-one (37): UV (CH3OH): λmax 218, 
232, 296 nm; 1H NMR (CDCl3), δ (ppm) 1.08 (s, 3H), 1.46-1.61 (m, 4H), 1.79 (m, 1H), 2.00 (m, 
2H), 2.17 (m, 1H), 2.40 (m, 1H), 2.42 (m, 1H), 2.55 (m, 2H), 2.85 (m, 1H), 3.13 (m, 1H), 3.74 (t, 
1H), 7.67 (s, 1H); 13C NMR (CDCl3), δ (ppm) 11.5 (CH3), 25.0 (CH2), 25.8 (CH2), 31.9 (CH2), 36.1 
(CH2), 36.1 (CH2), 38.6 (CH2), 44.2 (C), 50.6 (CH), 51.3 (CH), 81.1 (CH), 108.0 (C), 113.9 (C), 
115.6 (C), 135.4 (CH), 142.4 (C),. 149.9 (C), 212.6 (C); ESI(−)MS m/z: 523 ([M−H]−, 100), 525 
([M+2−H]−, 265), 527 ([M+4−H]−, 223), 529 ([M+6−H]−, 92). 
2,4-dibromoestrone (38): UV (CH3OH): λmax 225, 290 nm; 1H NMR (CDCl3), 0.90 (s, 3H), 1.46-
1.52 (m, 4H), 1.63 (m, 1H), 1.96 (m, 1H), 2.04-2.18 (m, 3H), 2.26 (m, 1H), 2.33 (m, 1H), 2.46-2.60 
(m, 2H), 2.67 (m, 1H), 2.94 (m, 1H), 7.40 (s, 1H); 13C NMR (CDCl3), δ (ppm) 13.7 (CH3), 21.5 
(CH2), 26.1 (CH2), 26.4 (CH2), 30.9 (CH2), 31.4 (CH2), 35.8 (CH2), 37.3 (CH), 43.9 (CH), 47.8 (C), 
50.2 (CH), 106.5 (C), 113.2 (C), 128.5 (CH), 134.7 (C), 136.4 (C), 147.2 (C), 220.0 (C); ESI(−)MS 
m/z: 425 ([M−H]−, 100), 427 ([M+2−H]−, 146), 429 ([M+4−H]−, 93) 
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SOLVENT FREE REACTIONS 
 
 
Oxidation of 17βE by FeNH4(SO4)2: General Procedure. A mixture of 17βE (50 mg, 0.2 mmol) 
and FeNH4(SO4)2 (177 mg, 0.4 mmol) was finely powdered by agate mortar and pestle. The mixture 
was then put in a test tube and kept at 150 °C for 6 h. The solid was diluted with water and (60 mL) 
and extracted with ethyl acetate (3x40 mL). The combined organic layers were dried over 
anhydrous sodium sulphate and concentrated under reduced pressure. The crude product gave the 
pure product 39 (30 mg, 67 % yield). 
 
3’-methyl-7-hydroxy-1,2-cyclopentenophenanthrene (39): UV: λmax (CH3OH) 259 nm; 1H-NMR 
(CDCl3) δ(ppm) : 1.38 (d, 3H ), 1.80 (m, 1H), 2.52 (m, 1H), 3.19 (m, 1H), 3.33 (m, 1H), 3.40 (m, 
1H), 7.19 (dd, J = 8.8, 2.8 Hz, 1H), 7.23 (d, J = 2.8 Hz, 1H), 7.49 (d, J = 8.4 Hz, 1H), 7.61(d, J = 
8.8 Hz, 1H), 7.74 (d, J = 8.8 Hz, 1H), 8.45 (d, J = 8.4 Hz, 1H), 8.56 (d, J = 8.8 Hz, 1H); 13C-NMR 
(CDCl3) δ(ppm) : 20.5 (CH3), 29.9 (CH2), 34.3 (CH2), 40.1 (CH), 111.8 (CH), 116.6 (CH), 120.8 
(CH), 122.3 (CH), 124.3 (CH), 124.7 (CH), 125.4 (C), 126.0 (CH), 127.6 (C), 129.1 (C), 133.0 (C), 
140.3 (C), 145.7 (C), 153.7 (C); ESI(-)MS: m/z 247 [M-H]−. 
 
 
Oxidation of 17βE by FeCl3: General Procedure. A mixture of 17βE (50mg, 0.2 mmol) and 
FeCl3 (400 mg, 1.6 mmol) was finely powdered by agate mortar and pestle. The mixture was then 
put in a test tube and kept at 60 °C for 6 h. The solid was diluted with water and (60 mL) and 
extracted with ethyl acetate (3x40 mL). The combined organic layers were dried over anhydrous 
sodium sulphate and concentrated under reduced pressure. The crude product was purified by PLC 
(eluant A) to afford product 40 (Rf = 0.47, 3 mg, 5 % yield) and 41 (Rf = 0.19, 26 mg, 25% yield). 
 
4,15-dichloroestra-1,3,5(10)-trien-3,17β-diol (40): UV: λmax (CH3OH) 209, 234, 264, 290, 302, 
315, 337, 356 nm; 1H-NMR (CD3OD) δ (ppm): 1.00 (s, 3H), 1.70 (m, 1H), 2.27 (m, 1H), 2.75 (m, 
1H), 2.93 (m, 1H), 3.22 (m, 1H), 3.40 (m, 1H), 4.11 (t, 1H), 7.21(d, J = 9.2 Hz, 1H), 7.98 (d, J = 9.2 
Hz, H) 8.00 (d, J = 9.2 Hz, H), 8.57(d, J = 9.2 Hz, 1H); 13C-NMR (CD3OD) δ (ppm): 16.3 (CH3), 
25.9 (CH2), 36.5 (CH2), 47.2 (CH2), 49.9 (C), 79.8 (CH), 116.1 (C), 120.0 (CH), 122.4 (C), 122.7 
(CH), 126.1 (CH), 127.3 (C), 128.0 (CH), 129.7 (C), 133.6 (C), 134.5 (C), 138.3 (C), 153.3 (C); 
ESI(-)MS m/z 333 ([M-H]−, 100), 335 ([M+2-H]−, 65), 337 ([M+4-H]−, 12)  [ ]25Dα = -64.8° (c 
0.42×10-5, MeOH) 
 
4,4’-di[15-chloroestra-1,3,5(10)-trien-3,17β-diol] (41): UV: λmax (CH3OH) 257, 273, 303, 315 
nm; 1H-NMR (CD3OD) δ (ppm): 1.00 (s, 6H), 1.72 (m, 2H), 2.25 (m, 2H), 2.70 (m, 2H), 2.87 (m, 
2H), 3.23 (m, 2H), 3.46 (m, 2H), 4.11 (t, 2H), 6.90 (d, J = 9.6 Hz, 2H), 7.31 (d, J = 9.2 Hz, 2H), 
8.13 (d, J = 9.2 Hz, 2H), 8.22 (d, J = 9.6 Hz, 2H); 13C-NMR (CD3OD) δ (ppm): 15.9 (2 CH3), 25.5 
(2 CH2), 36.3 (2 CH2), 46.8 (2 CH2), 49.0 (2 C), 79.5 (2 CH), 117.6 (2 C), 119.6 (2 CH), 121.9 (2 
C), 124.5 (2 CH), 126.2 (2 C), 126.5 (2 CH), 127.2 (2 CH), 129.1 (2 C), 134.3 (2 C), 135.9 (2 C), 
138.3 (2 C), 155.1 (2 C); ESI(-)MS m/z 597 ([M-H]−, 100), 599 ([M+2-H]−, 70), 601 ([M+4-H]−, 
20); [ ]25Dα = -188.37°(c 0.43×10-5, MeOH). 
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